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ABSTRACT 
 
ANGELA M. DEVEAUGH-GEISS: Depression and Comorbid  
Panic and Pain in Primary Care Patients  
(Under the direction of Suzanne L. West, PhD and William C. Miller, MD, PhD) 
 
 Depression is a common and debilitating condition.  Though the goal of depression 
treatment is remission, many patients do not achieve this outcome.1   This research focused 
on exploring how two common comorbid conditions, panic and pain symptoms, affect 
depression treatment outcomes in a primary care setting using data from an open-label 
longitudinal, comparative effectiveness study of three selective serotonin reuptake 
inhibitors.2    
 While baseline panic symptoms were not associated with depression outcomes 
(remission or partial response), persistent panic, or panic symptoms that were present at 
baseline and month 3, were associated with poorer depression outcomes, particularly 
remission.  Although we used a screening question to assess panic symptoms, the 
probabilistic sensitivity analysis suggests that the results are robust to varying sensitivity and 
specificity within a large range of plausible values.   
 Baseline pain symptoms were associated with worse depression outcomes, with 
evidence of an incremental response with increasing pain severity.  Furthermore, the 
improvement of pain in the first month of treatment was associated with better depression 
response.  Though there is no available information on the minimal clinically important 
difference on the Patient Health Questionnaire-15 pain subscale, we explored two different 
iv 
cut-points and found similar results with each.  Furthermore, there was evidence that a more 
conservative cut-point resulted in a stronger association of pain improvement and depression 
outcomes, suggesting that even small changes in pain result in improved depression 
outcomes. 
 Across all analyses (panic and pain), there was evidence of incremental response, 
with a stronger association in the remission vs. nonresponse comparison and a weaker 
association in the partial response vs. nonresponse comparison. 
 These findings suggest that comorbid panic (particularly persistent panic) and pain 
symptoms are associated with worse depression outcomes in the maintenance phase of 
treatment.  Furthermore, improvements in pain are associated with improved depression 
outcomes.  Consequently, improvement in panic and pain symptoms may be important for 
improved depression outcomes and primary care physicians should be attuned to the presence 
of these symptoms when making treatment decisions. 
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CHAPTER I 
STATEMENT OF SPECIFIC AIMS 
CHAPTER   
I.  STATEMENT OF SPECIFIC AIMS 
 Depression is a common and debilitating condition affecting approximately 121 
million people worldwide.3  The goal for depression treatment is remission; however, a large 
“real world” antidepressant effectiveness trial demonstrated that approximately 30% of 
patients experienced remission regardless of treatment setting (primary vs. specialty care).1  
 Almost half of the outpatient care for depression is provided by primary care 
providers (PCPs)4 and nearly 10% of primary care office visits are depression-related.5  
Additionally, the annual number of antidepressant visits is similar for psychiatrists and 
PCPs6 and SSRIs are commonly prescribed in primary care settings.7  Despite the 
prevalence of SSRI use in primary care, most of the available studies did not capture 
information on antidepressant treatment or did not study the effects of SSRIs.  
Furthermore, the average visit to a PCP lasts about 15 to 20 minutes8, 9 and treatment for 
depression must compete with other demands. Therefore, given the time constraints of 
primary care practice, it is important to explore what factors affect depression treatment 
outcomes in this setting.
2 
 Comorbid anxiety (including comorbid panic disorder) and comorbid pain are 
common in depressed patients and may lead to poorer treatment outcomes.10-13  While 
comorbid anxiety may be more common in depressed patients treated in primary care vs. 
specialty care, the prevalence of comorbid pain appears to be similar regardless of 
treatment setting.10, 14, 15  However, most studies of depression and comorbid panic or 
pain focus on the treatment of depression in specialty care or clinical trials settings, 
which lack generalizability to primary care settings or to general clinical practice.  This 
study expanded on previous research by utilizing a large, naturalistic study of depressed 
primary care patients.  The objective of this study was to examine how panic symptoms, 
pain symptoms, and improvements in pain affect depression outcomes (remission, partial 
response, or nonresponse) in primary care patients treated for depression with one of 
three SSRIs (sertraline, paroxetine, or fluoxetine) at month 6, during the maintenance 
phase of depression treatment.  
 Specific Aim 1: To determine the effect of panic symptoms on depression 
treatment outcomes at month 6.  Hypothesis 1: Depressed patients with panic symptoms 
will have worse outcomes than depressed patients without panic symptoms.  
 Specific Aim 2: To determine the effect of baseline pain symptoms on depression 
treatment outcomes at month 6.  Hypothesis 2: Depressed patients with baseline pain 
symptoms will have worse outcomes than depressed patients without baseline pain 
symptoms. 
 Specific Aim 3: To determine the effect of early improvement in pain (baseline to 
month 1) on depression treatment outcomes at months 1 and 6.  Hypothesis 3: Depressed 
3 
patients without early improvement in pain will have worse outcomes at months 1 and 6 than 
depressed patients with early improvement in pain. 
 To address these aims, we used existing data from A Randomized Trial Investigating 
SSRI Treatment (ARTIST).2  ARTIST was a 9-month longitudinal effectiveness study 
comparing three SSRIs for the treatment of depression in a primary care setting (n=573).  
ARTIST included well-validated depression measures including the Mental Component 
Summary (MCS), the Patient Health Questionnaire-9 (PHQ-9), and the Symptom Checklist 
20 (SCL-20).  ARTIST also included measures of panic and pain; panic was measured using 
a screening question from the Brief Patient Health Questionnaire (BPHQ) and pain was 
measured using the Patient Health Questionnaire-15 (PHQ-15). 
 CHAPTER II 
 
BACKGROUND AND SIGNIFICANCE 
II.  BACKGROUND AND SIGNIFICANCE 
Depression  
Diagnostic criteria for Major Depressive Disorder 
 A Major Depressive Episode (MDE) is characterized by a number of symptoms 
including depressed mood, loss of interest or pleasure, weight loss or gain, insomnia or 
hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of 
worthlessness or excessive guilt, inability to concentrate, or recurrent thoughts of death.16  
The DSM-IV (Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition) criteria 
for an MDE is the presence of 5 or more of these symptoms during the same 2-week period 
that represents a change from previous functioning and at least one of the symptoms is either 
depressed mood or loss of interest or pleasure.16  Major depressive disorder (MDD) is the 
presence of a single MDE “that is not better accounted for by schizoaffective disorder and is 
not superimposed on schizophrenia, schizophreniform disorder, delusional disorder, or 
psychotic disorder not otherwise specified” and “there has never been a manic episode, a 
mixed-episode, or a hypomanic episode.”16 
 
Depression is common and debilitating 
 According to the National Comorbidity Survey-Replication (NCS-R), the lifetime 
prevalence of MDD in the United States is 16.2%.17  Depression is not only common, it is 
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also debilitating.  The World Health Organization Global Burden of Disease Study ranked 
depression the fourth most disabling disease in 1990.18  Depression is expected to be the 
second leading cause of disability in the world by the year 2020; today, depression is the 
second leading cause of disability adjusted life years in those aged 15 to 44.18 
 
Primary care is a key setting for the management of depression 
 Almost 10% of all primary care office visits are depression-related and PCPs 
provide nearly half the outpatient care for depressed patients.4, 5  According to the 1995 
and 1996 National Ambulatory Medical Care Survey, the annual number of 
antidepressant visits is similar for psychiatrists and PCPs.6  However, the average visit to 
a PCP lasts approximately 15 to 20 minutes8, 9, 19 and recognition and treatment of 
depression must compete with other demands.20-23   
 While several studies have shown that depression treated in primary care is 
different than depression treated in specialty care in terms of severity and presenting 
symptoms or demographics,24-26 a direct comparison of the two treatment settings 
revealed that severity of depression was similar among patients treated in primary care 
vs. specialty care.27, 28 
 
The goal of depression treatment is remission 
 Regardless of treatment setting, the goal of depression treatment is remission, or 
absence of depressive symptoms.  However, a large “real world” antidepressant effectiveness 
trial demonstrated that approximately 30% of patients experience remission.1  Remission 
rates were similar regardless of treatment setting - primary vs. specialty care.  Therefore, in 
6 
order to achieve remission, it is important to understand what factors influence depression 
treatment outcome. 
 
Depression and Comorbid Anxiety 
Comorbid anxiety is common in depressed patients 
 Comorbid anxiety disorder [e.g., generalized anxiety disorder (GAD), obsessive-
compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), and 
social anxiety disorder (SAD) (see Table 1)] or anxiety symptoms (symptoms of an 
anxiety disorder) are common in depressed patients.  In the NCS and NCS-R, almost 60% 
of patients with lifetime MDD had a comorbid anxiety disorder with even more patients 
experiencing comorbid anxiety symptoms.13  In depressed patients treated in a primary 
care setting, GAD and SAD appear to be the most common, although many patients 
suffer from comorbid panic disorder, which may be the most clinically important 
comorbid anxiety disorder.29, 30   
 
Table 1.  Characteristics of five common anxiety disorders31 
Disorder Characteristics 
GAD Chronic anxiety, exaggerated worry and tension 
OCD Recurrent, unwanted thoughts (obsessions) and/or repetitive 
behaviors (compulsions) 
Panic 
Disorder 
Unexpected repeated episodes of intense fear accompanied by 
physical symptoms (e.g., chest pain, heart palpitations, shortness of 
breath, dizziness, or abdominal distress) 
PTSD Anxiety that can develop after exposure to an event/ordeal in which 
grave physical harm occurred or was threatened 
SAD Overwhelming anxiety and excessive self-consciousness in 
everyday social situations 
 
7 
 Many studies of depression and comorbid anxiety group the anxiety disorders 
together rather than looking at the effect of individual anxiety disorders or study patients 
with depression and high anxiety scores (e.g., patients with high scores on the Hamilton 
Depression Scale Anxiety/Somatization Factor).  When anxiety disorders are grouped, it 
is impossible to examine the effect of individual anxiety disorders on depression 
treatment outcomes.  When anxiety is defined as a high anxiety score, the focus of the 
study is on symptoms of anxiety rather than an anxiety disorder.  Therefore, we included 
relevant background information on depression and comorbid anxiety defined as multiple 
anxiety disorders or anxious depression (depressed patients who report high levels of 
anxiety).  When available, we included information specific to depression and comorbid 
panic disorder, the focus of the current study. 
 
Anxiety may be more common in primary care vs. specialty care settings 
 In a large study conducted in both primary and specialty care (Sequenced 
Treatment Alternatives to Relieve Depression, STAR*D), anxious depression was 
significantly more common in women, Hispanics, non-single subjects, unemployed 
subjects, those with less schooling, those with more severe depression and those in 
primary-care settings; results were the same when the authors controlled for baseline 
depression severity.14, 15  The high prevalence of comorbid anxiety in depressed primary 
care patients, along with the clinical importance of panic disorder, underscores the need 
to understand the effect of depression and comorbid panic, particularly in primary care 
patients. 
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Comorbid anxiety may be associated with poor depression outcomes  
 In specialty care settings or in population-based studies, there is evidence that 
depression and comorbid anxiety are associated with more severe depressive symptoms 
or more depressive symptoms32-34 though not all studies support this difference.35-37  
Additionally, patients with depression and comorbid anxiety are less likely to experience 
response or remission, 38-42 have a lower rate of recovery,33, 43 or have a slower response 
to treatment. 34, 44, 45   Additionally, the presence of subthreshold anxiety (anxiety that 
does not meet the DSM criteria for an anxiety disorder) may also lead to worse 
depression outcomes.46    While there is no evidence that patients with depression and 
comorbid anxiety experienced higher rates of relapse/recurrence of their depressive 
episodes,37, 45 patients with anxiety remaining at remission of the index episode of 
depression were found to have a shorter time to relapse/recurrence.37   
 Like patients with depression and comorbid anxiety, patients with depression and 
comorbid panic have more severe depression,47-51 however there is some evidence to the 
contrary.42  Additionally, patients with depression and comorbid panic may be less likely 
to experience recovery or experience a slower recovery38, 42, 45, 48, 51-53 and have a more 
severe course of depression.47, 54  In a study of patients visiting primary care or specialty 
care, depressed patients with comorbid anxiety were less likely to remit in the first year.43  
However, there is some evidence that depression and comorbid panic are not associated 
with worse depression outcomes.38, 50  However, there is also evidence that patients with 
comorbid panic are less likely to respond42 or experience a longer time to response.51  
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Primary care patients with depression and comorbid anxiety can be difficult to treat 
 Studies in primary care have evaluated several different interventions for patients 
with comorbid depression and anxiety with mixed results.  Some studies suggest that the 
presence of comorbid anxiety is associated with greater depressive severity55 or worse 
depression outcomes,56 however, not all studies support a difference.30  Additionally, 
patients with depression and comorbid anxiety are less likely to experience 
response/remission or experience slower recovery.30, 55, 57, 58  While primary care patients 
with depression and comorbid anxiety were more likely to experience relapse of their 
depression, anxiety was not associated with relapse in a regression analysis which 
controlled for sex, age, chronic disease score, study group and intervention status.59  
Similarly, anxiety symptoms were an important predictor of shorter depression-free time 
and higher mean severity of depression symptomatology when considered alone, but 
anxiety was not an important predictor in the multiple regression analysis.60 
 Like depression and comorbid anxiety, studies in primary care settings have 
examined depression and comorbid panic with mixed results.  Both panic attacks and 
panic disorder are associated with more severe depressive illness and greater disability.61 
Similarly, a lifetime history of panic disorder is associated with more severe depression,62 
greater impairment,62 and poorer treatment response.55, 63  However, not all evidence 
supports a difference in outcomes for patients with depression and comorbid panic vs. 
depression alone.  While comorbid panic was associated with more severe depression, the 
presence of panic was not associated with response rates after 12 months of treatment64  
and panic was not associated with persistence of depression.65  
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Suicide is common among patients with depression and comorbid anxiety 
 It has been reported that, in patients with depression, the presence of comorbid 
panic attacks66, 67 and lifetime anxiety disorders68 are associated with an increased risk of 
suicide.  In depressed primary care patients, the presence of comorbid panic disorder or 
panic attacks are associated with an increased risk of suicidal ideation69  and patients with 
both depression and panic disorder have a higher rate of suicidal ideation than patients 
with either panic disorder or major depression alone.70  With regard to suicide attempts, 
patients with both depression and panic disorder have a higher rate than patients with 
either panic disorder or major depression alone.67, 71   
 
Limitations of the available longitudinal data on depression and comorbid anxiety 
 There are limitations to the available evidence on outcomes for primary care 
patients with depression and comorbid anxiety.  Only three of the longitudinal studies 
included more than 250 patients59, 61, 64 and only two of these studies was designed to 
look specifically at depression and comorbid panic.61, 64  Furthermore, most of the studies 
either did not capture treatment information or evaluated treatments that are less 
commonly used in PC (Interpersonal therapy, nortriptyline).  Table 2 presents each 
longitudinal primary care study along with a summary of the study design and the 
author’s conclusions. 
 We expanded on the available evidence by utilizing a large sample (n=573) of 
primary care patients who were treated in a naturalistic manner (patients were 
randomized to treatment but could have changes and additions to their medication).  We 
11 
explored outcomes during the maintenance phase of treatment (month 6) and whether 
adequacy of antidepressant treatment affected the results. 
  
Table 2.  Longitudinal studies of depression and anxiety in primary care 
 
First Author,  
Title, Citation 
Study Design (duration), 
Population,  
Intervention 
Findings Conclusions and Limitations 
Conradi HJ. 
Prediction of the three-
year course of recurrent 
depression in primary 
care patients: Different 
risk factors for different 
outcomes.  Journal of 
Affective Disorders.  
2007; 105: 1-3.  276-
271.72 
Prospective cohort study (3 years) 
 
123 depressed primary care patients 
(18 to 70 years of age) 
 
Usual care vs. Usual care plus low-
intensity psycho-educational 
prevention program 
Higher anxiety (as measured by the 
anxiety scale of the SCL-90) was a 
predictor of shorter depression-free 
time and higher mean severity of 
depressive symptomatology during 
follow-up.   
Conclusions: Suggests that 
depression and comorbid baseline 
anxiety symptoms are associated with 
shorter depression-free time and 
worse treatment outcomes. 
Limitations:  Results differed in the 
multiple regression analysis and the 
bivariate analysis.  Measured anxiety 
symptoms not the presence of 
specific anxiety disorders. 
McIntyre RS. 
Residual Anxiety 
Symptoms in Depressed 
Primary Care Patients. 
Journal of Psychiatric 
Practice.  2007.  13 (2): 
125-128.56 
Prospective cohort study (8 weeks) 
 
454 depressed primary care patients 
(18 years of age and older) 
 
Treatment chosen at the discretion of 
the PCP 
The baseline composite anxiety ratio 
(anxiety score as measured by 6 
Hamilton Depression Rating Scale 
(HAMD) items divided by total 
HAMD scores) did not correlate with 
the probability of depression 
remission at endpoint.  There was an 
inverse correlation between anxiety 
ratio at endpoint and probability of 
remission at endpoint. 
Conclusions: Suggests that 
depression and baseline comorbid 
anxiety symptoms are associated with 
worse treatment outcomes; 
improvement in anxiety symptoms 
appears to be associated with 
improved depression outcomes. 
Limitations: Only 8 weeks of 
follow-up, analyses did not control 
for treatment, completer analysis 
only. 
12 
  
 
First Author,  
Title, Citation 
Study Design (duration), 
Population,  
Intervention 
Findings Conclusions and Limitations 
Alexopoulos GS.  
Remission in depressed 
geriatric primary care 
patients: a report from 
the PROSPECT study.  
Am J Psychiatry, 2005.  
162: 718-724.58 
Prospective cohort study (4 months) 
 
215 depressed primary care patients 
(60 years of age and older)  
 
PROSPECT intervention (first step: 
citalopram or IPT) 
vs. usual care 
Patients with limitations in physical 
and emotional aspects of functioning, 
hopelessness, and anxiety were less 
likely to achieve remission. 
Conclusions: Suggests that 
depression and comorbid anxiety are 
associated with worse treatment 
outcomes in the elderly. 
Limitations: Small sample size, only 
4 months of follow-up, usual care 
consisted of educational materials 
(videotape and printed materials on 
geriatric depression and treatment)  
Hegel MT. 
Impact of comorbid 
panic and posttraumatic 
stress disorder on 
outcomes in 
collaborative care for 
late-life depression in 
primary care.  Am J Ger 
Psychiatry.  13 (1): 48-
58. 
Prospective cohort study (12 months) 
 
1,801 depressed primary care patients 
(60 years of age and older)  
 
IMPACT intervention (collaborative, 
stepped-care approach) 
 
Patients with PTSD had a more 
delayed response compared to 
patients without PTSD, patients with 
panic had similar outcomes to 
patients with no panic. 
Conclusions: Suggests that 
depression and comorbid PTSD are 
associated with worse treatment 
outcomes in the elderly; there is no 
evidence that panic leads to worse 
outcomes. 
Limitations: panic and PTSD based 
on screening instruments and not 
clinical diagnoses, studied treatments 
that are not as commonly used in 
primary care as SSRIs. 
Brown C. 
 Factors associated with 
symptomatic 
improvement and 
recovery from major 
depression in primary 
care patients.  Gen Hosp 
Psychiatry, 2000.  22: 
242-250.57 
Prospective, randomized controlled 
study (8 months) 
 
181 primary care patients (18 to 64 
years of age)  
 
IPT vs. nortriptyline vs.  
usual care 
Patients with no history of panic or 
GAD who perceived internal control 
of health and were randomized to 
standardized treatment were more 
likely to recover by month 8 
(controlling for baseline depression 
severity).  Anxiety was not a 
predictor of recovery for patients 
treated with nortriptyline, although it 
was with IPT. 
Conclusions: Suggests that 
depression and comorbid anxiety are 
associated with worse treatment 
outcomes. 
Limitations: small sample size, 
studied treatments that are not as 
commonly used in primary care as 
SSRIs. 
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First Author,  
Title, Citation 
Study Design (duration), 
Population, 
Intervention 
Findings Conclusions and Limitations 
Gaynes BN. 
Does a coexisting 
anxiety disorder predict 
persistence of 
depressive illness in 
primary care patients 
with major depression?  
Gen Hosp Psychiatry. 
1999. 21: 158-167.30   
Prospective cohort study (12 months) 
 
85 primary care patients (18 to 64 
years of age) who screened positive 
for depression 
 
No intervention 
The risk of depression at month 12 
(persistent depression) was 44% 
higher in patients with comorbid 
anxiety.  There was no difference in 
baseline depression severity. 
Conclusions: Suggests that 
depression and comorbid anxiety are 
associated with worse treatment 
outcomes. 
Limitations: Small sample size, did 
not capture treatment for all patients. 
Lecrubier Y.   
Panic and depression: a 
worldwide primary care 
perspective. Int Clin 
Psychopharm. 1998. 13 
(suppl 4): S7-S11.61 
Cross-sectional study with follow-up 
at 3 and 12 months (3-12 months) 
 
5,447 primary care patients (15 to 65 
years of age) 
 
No intervention 
Comorbid panic disorder and 
depression was associated with 
greater depressive severity at baseline 
and more disability days than those 
with either disorder alone.  Similar 
results were seen for patients with 
depression and panic attacks not 
reaching criteria for panic disorder. 
Conclusions: Suggests that 
depression and comorbid panic 
disorder and panic attacks are 
associated with greater depressive 
severity and disability than either 
alone.   
Limitations: Results appear to be 
based on cross sectional data only; 
however, there was a low response 
rate at month 12 (62%). 
Lin EH.   
Relapse of depression in 
primary care rate and 
clinical predictors. Arch 
Fam Med. 1998. 7: 443-
449. 59 
Prospective cohort study (19 months) 
 
251 primary care patients (18 to 80 
years of age) with major depression  
 
Antidepressant medication 
Significantly more patients who 
relapsed had a history of GAD/panic 
disorder; anxiety was not a 
significant predictor of relapse in the 
logistic regression model (the 2 main 
predictors were persistence of 
depressive symptoms and a history of 
≥2 depressive episodes or chronic 
mood symptoms for 2 years). 
Conclusions: Provides some 
evidence that anxiety (GAD/panic) is 
associated with relapse. 
Limitations: Small sample size, no 
details about medication. 
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First Author,  
Title, Citation 
Study Design (duration), 
Population,  
Intervention 
Findings Conclusions and Limitations 
Brown C. 
Phenomenology and 
severity of major 
depression and 
comorbid lifetime 
anxiety disorders in 
primary medical care 
practice. Anxiety.  1996.  
2: 210-218.62 
Prospective, randomized controlled 
study (Follow-up undefined ) 
 
276 primary care patients (age range 
undefined) with major depression 
 
IPT vs. nortriptyline vs. usual care 
Panic disorder was associated with 
greater depressive severity in patients 
with MDD (with or without GAD).  
Psychosocial functioning was also 
impaired in patients with MDD and 
panic disorder vs. MDD alone.  
Depressed patients with panic 
disorder differed from depressed 
patients with or without GAD in 
somatic symptoms, functional 
impairment, suicidality, and mood 
disturbance but not on cognitive 
symptoms or depression.   
Conclusions: Suggests that 
depression and comorbid anxiety, 
and panic in particular, are associated 
with greater depression severity and 
greater impairment in a number of 
different domains. 
Limitations: Small sample size; 
studied treatments which may not be 
as commonly used in primary care as 
SSRIs. 
Brown C. 
Treatment outcomes for 
primary care patients 
with major depression 
and lifetime anxiety 
disorders.  Am J 
Psychiatry. 1996. 153 
(10): 1293-1300.55 
Prospective, randomized, 
longitudinal, controlled study (8 
months) 
 
157 primary care patients (18-64 
years of age) with major depression  
 
IPT vs. nortriptyline 
Both treatments were effective for 
the treatment of depression.  Lifetime 
panic disorder was associated with 
longer time to recovery and lack of 
response to treatment. 
Conclusions: Suggests that 
depression and comorbid anxiety, 
and panic in particular, are associated 
with worse treatment outcomes. 
Limitations: Small sample size; 
studied treatments which may not be 
as commonly used in primary care as 
SSRIs. 
Katon W.   
The predictors of 
persistence of 
depression in primary 
care.  Journal of 
Affective Disorders.  
1994. 31:81-90.65 
Prospective cohort study (4 months) 
 
164 depressed primary care patients 
(18 to 75 years of age) 
 
Not Applicable (NA) 
Symptoms of panic disorder were not 
a predictor of persistent depression.   
Conclusions: Suggests that 
symptoms of panic disorder may not 
be associated with depression 
treatment outcomes. 
Limitations: Small sample size, 
panic disorder determined using 
screening questions; the model did 
not control for treatment. 
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First Author, 
Title, Citation 
Study Design (duration), 
Population,  
Intervention 
Findings Conclusions and Limitations 
Zung WWK.  
The comorbidity of 
anxiety and depression 
in general medical 
patients: a longitudinal 
study.  J Clin Psych. 
1990. 61 (supp 6): 77-
80. 
Prospective, cohort study (12 
months) 
 
112 depressed males in a general 
medical practice (age range not 
presented) 
 
NA 
Depressed patients who improved (as 
measured by the Zung Self-Rating 
Depression Scale) had a decrease in 
their anxiety symptoms (as measured 
by the Zung Self-Rating Anxiety 
Scale).  Depressed patients who had a 
worsening of depressive symptoms 
also experienced a worsening of 
anxiety symptoms. 
Conclusions: Suggests that 
improvement in anxiety symptoms 
accompanies improvement in 
depressive symptoms. 
Limitations:  While follow-up 
continued for 12 months, it is unclear 
what time point is used for the 
calculation of the change scores for 
depression and anxiety.  
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The Overlap of Depression and Anxiety 
There is some symptom overlap in depression and anxiety 
 Whether depression and anxiety are distinct disorders or clinical variants of the 
same disorder has been debated for more than 30 years.  While the early literature (1970s 
and 1980s) supported depression and anxiety as separate entities, some of the more recent 
literature suggests that anxiety and depression should be considered together because of 
the significant comorbidity of both disorders.73  However, the recent psychiatric literature 
also suggests that there are symptoms specific to each disorder, lending credence to 
diagnostic separation between the two disorders.74   Anxiety disorders tend to precede 
depressive disorders, which lends support to the conditions as separate disorders rather 
than an epiphenomenon.75 
 A recent review of the genetic epidemiology literature related to the comorbidity 
of anxiety and depression revealed 23 twin studies and 12 family studies.75  Middeldorp 
et al. concluded that anxiety disorders and major depressive disorder are distinct entities 
rather than “alternative phases of one disorder.”75  The comorbidity between anxiety 
disorders and depression is explained in part by overlapping genetic etiological factors.   
 
The Treatment of Depression and Anxiety 
SSRIs and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) are indicated for the 
treatment of both depression and anxiety 
 There are a number of SSRIs indicated for the treatment of depression including 
fluoxetine, paroxetine, sertraline, fluvoxamine maleate, citalopram, and escitalopram oxalate, 
many of which are also indicated for the treatment of anxiety disorders (Table 3).  For 
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patients who have depression with comorbid anxiety, some clinicians suggest that treatment 
should begin with monotherapy using either an SSRI or SNRI such as duloxetine or 
venlafaxine as these agents are effective in the treatment of both disorders.76  In addition, the 
use of a single agent can minimize adverse effects that may be associated with dual therapy.76  
  
 
Table 3.  Approved indications for SSRIs/SNRIs* 
 
SSRI/SNRI Depression Panic 
Disorder 
SAD OCD GAD PTSD 
Citalopram 77 √      
Escitalopram 78 √    √  
Fluoxetine 79 √ √  √   
Fluvoxamine 80 √   √   
Paroxetine 81 √ √ √ √ √ √ 
Sertraline 82 √ √ √ √  √ 
Venlafaxine 83 √  √  √  
Duloxetine 84 √    √  
* SAD=seasonal affective disorder, OCD=obsessive compulsive disorder, GAD=generalized anxiety disorder, 
PTSD=posttraumatic stress disorder 
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SSRIs are commonly prescribed by PCPs 
 Approximately 65% of antidepressant prescriptions in primary care are for SSRIs 
SSRIs.7  Other newer antidepressants (bupropion, mirtazapine, nefazadone, and 
venlafaxine) accounted for only 17% of antidepressant prescriptions.7  Many of the 
SSRIs and SNRIs are indicated for the treatment of both depression and anxiety 
(including panic disorder for fluoxetine, paroxetine, and sertraline, see Table 3).  Given 
the Food and Drug Administration (FDA) approved indications for the SSRIs, along with 
the prevalence of SSRI use in primary care, it is important to understand the effect of 
depression and comorbid panic disorder in primary care patients treated with SSRIs.7   
 
Depression and Comorbid Pain 
Comorbid pain symptoms are common in depressed patients  
 More than 50% of depressed patients experience comorbid pain including, but not 
limited to, headache, back pain, chest pain, gastrointestinal discomfort, and other body 
aches10, 11, 85, 86  and the prevalence of pain is unrelated to the study setting (primary vs. 
specialty care).10  While some suggest that physical symptoms should be considered as an 
important part of depression and there are many symptoms of depression and pain that 
overlap (insomnia, fatigue, psychomotor agitation/retardation, etc.), the DSM-IV criteria for 
a depressive episode includes only a few somatic symptoms (e.g., fatigue, sleep 
disturbances).87  In fact, depression may often go unrecognized when it presents mainly as 
physical symptoms.88  There is evidence that depression is a risk factor for pain and that pain 
leads to development of depression.87  
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Comorbid pain is associated with poor depression outcomes 
 Data from the Epidemiologic Catchement Area Study,89 the Canadian general 
population,90 and a random sample of health maintenance organization members in 
Michigan91 support an association between depression and abdominal pain, chronic back 
pain, or migraine, respectively.  However, a Swedish-based population study found no 
association between lifetime migraine and depression in women aged 40-74 years of 
age.92  Additional epidemiologic evidence has demonstrated that the presence of pain 
complaints (e.g., abdominal pain, headache pain, back pain, chest pain, and facial pain) 
are associated with more depression severity93, 94 as well as the duration95 and course94 of 
the depressive episode.  
 Clinical trials have demonstrated that patients who experienced improvements in 
pain also experienced higher depression remission rates96 and that pain is associated with 
longer time to remission of recurrent depression.97  In an inpatient study of depression 
and pain, depressed nonresponders reported greater pain levels at baseline and at 10 days 
of follow-up.98 Furthermore, almost all depressed patients with residual symptoms after 
partial remission also had mild to moderate physical symptoms.99  However, another 
clinical trial of late-life depression did not find any association of pain with time to 
depression response or with suicidality.100 
 
Primary care patients with depression and comorbid pain can be difficult to treat 
 While population-based surveys have demonstrated that baseline pain is 
associated with greater depression severity, few studies have evaluated the effect of pain 
on depression treatment outcomes in primary care settings.10  Longitudinal evidence 
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support that pain improvement is associated with a reduction in depressive symptoms and 
that patients without improvement in pain are less likely to experience remission.101-103  
 The effects of baseline pain and changes in pain were also evaluated in ARTIST, 
the same dataset that was used for the current project.  The ARTIST study is described in 
more detail in Chapter 3.  Bair and colleagues reported that pain severity was associated 
with baseline depression severity and that having pain at baseline was a predictor of 
depression treatment response at 3 months of treatment.104  Pain symptoms decreased 
during the first month of treatment and then remained fairly constant from month 1 to 
month 9.105  Patients who experienced depression remission or partial response at months 
1 and 3 had significantly greater improvement in their pain symptoms than 
nonresponders.  The difference in pain improvement was similar for patients 
experiencing remission and partial response.  It is important to note that the analyses did 
not control for anxiety symptoms, and did not take treatment dose, duration, or changes 
to medication into account.   
 
Limitations of the available longitudinal studies of depression and comorbid pain 
 There are several limitations to the available evidence.  Only two longitudinal 
studies focused on pain in depressed patients (as opposed to depression in patients with 
pain).104, 105  Two additional studies focused on the presence of depression in patients 
seeking treatment for pain in a primary care setting.101, 103  Table 4 presents each 
longitudinal, primary care study along with a summary of the study design and the 
author’s conclusions. 
 Table 4.  Longitudinal studies of depression and pain in primary care 
 
First Author,  
Title, Citation 
Study Design (duration), 
 Population, Intervention Key Findings Conclusions and Limitations 
Bair MJ. 
Impact of pain on 
depression 
treatment 
response in 
primary care.  
Psychosom Med.  
2004.  66 (1): 17-
22.104 
Prospective, randomized, clinical trial 
(ARTIST) (9 months)  
 
573 clinically depressed patients (≥18 
years of age) 
 
Paroxetine, sertraline, fluoxetine 
69% of depressed patients had baseline 
pain.  ORs for poor depression response 
at month 3 were 1.5 (mild pain), 2.0 
(moderate pain), and 4.1 (severe pain) 
(all compared to no pain).   
Conclusions: Suggests that pain 
symptoms are common in depressed 
patients; severity of pain is associated 
with depression treatment response 
after 3 months of treatment.   
Limitations: Only evaluated depression 
treatment outcomes after 3 months of 
treatment; analyses did not control for 
the presence of anxiety. 
Greco T. 
The outcome of 
physical 
symptoms with 
treatment of 
depression.  J Gen 
Intern Med. 2004. 
19 (8): 813-818.105 
Prospective, randomized, clinical trial 
(ARTIST) (9 months) 
 
573 clinically depressed patients (≥18 
years of age) 
 
Paroxetine, sertraline, fluoxetine 
Pain symptoms decreased during the 
first month of treatment and then 
remained fairly constant through month 
9.  Patients who experienced partial 
depression response and remission had 
greater improvement in pain than 
patients who were nonresponders. 
Conclusions: Suggests that pain 
symptoms are common and tend to 
improve in the first month of treatment 
with an SSRI.   
Limitations: Only evaluated the effect 
of depression treatment outcomes on 
pain symptoms at months 1 and 3; 
analyses did not control for the 
presence of anxiety. 
Von Korff M. 
The relationship 
between pain and 
depression.  Br J 
Psychiatry. 1996. 
30: 101-108.102  
Review of epidemiologic studies 
(population based and primary care) 
  
Unknown study design, results from 
poster by Cherkin et al., which is 
summarized, in this review article. 
 
No Intervention. 
Depression scores appear to decrease as 
pain improves; depression scores 
appear to be lower in patients without 
pain compared to those with pain. 
Conclusions: Suggests an association 
between chronic pain and depression. 
Limitations: This is a review article of 
studies of depression and pain.  The 
studies focus on depression levels 
among patients with pain rather than 
pain among patients with depression.   
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 First Author, 
Title, Citation Study Design (duration), 
 Population, Intervention Key Findings Conclusions and Limitations 
Von Korff M.  
Back pain in 
primary care: 
outcomes at 1 
year.  Spine. 1993. 
18: 855-862.101 
Prospective cohort study of patients in 
the Group Health Cooperative of Puget 
Sound Health Maintenance 
Organization (12 months) 
 
1128 primary care patients who sought 
treatment for back pain (18 to 75 years 
of age) 
 
No Intervention 
Patients with a higher pain level at 
baseline tended to have a higher level of 
depression.  Back pain outcome also 
appeared to be associated with 
depression level at follow-up, i.e., 
patients with back pain improvement 
had lower depression levels at follow-
up. 
Conclusions: Suggests that 
improvement in pain is associated with 
improvement in depression. 
Limitations: The focus was on 
depression levels among patients with 
back pain rather than on pain levels in 
depressed patients. 
Von Korff M. 
Grading the 
severity of chronic 
pain.  Pain.  1992.  
50: 133-149.103 
Prospective, longitudinal study of 
patients in the Group Health 
Cooperative of Puget Sound Health 
Maintenance Organization (12 months) 
 
2389 patients with back pain headache, 
or temporomandibular disorder  
 
No Intervention. 
Chronic pain grade was significantly 
associated with depression both at 
baseline and 1-year follow-up. 
Conclusions: Suggests an association 
between chronic pain and depression. 
Limitations: The focus was on 
depression levels among patients with 
pain (back pain, headache, or TMD 
disorder) rather than on pain levels in 
depressed patients. 
24 
  25 
Depression, Anxiety, and Pain 
There is overlap of Depression, Anxiety, and Pain  
 There is sparse evidence of an association between depression, anxiety, and pain 
(e.g., migraine).106-108  The association of anxiety and pain appears to be independent of other 
comorbid mental disorders including depression.109, 110 Furthermore, the relationship between 
anxiety111 and chronic pain (e.g., arthritis, migraine) or panic111, 112 and chronic pain may be 
even stronger than the relationship between depression and chronic pain. 111, 112  In a large 
cross-sectional study (n=5,808) of primary care patients with MDD, the prevalence of panic 
disorder was significantly higher in patients with MDD and chronic disabling pain than other 
respondents.113   By contrast, a large Swedish study found no association between lifetime 
migraine and panic disorder in women aged 40 to 74 years of age.92   
 
Limitations of the available longitudinal evidence on depression, panic, and pain 
 Overall, few studies are available which explore depression, panic, and pain despite 
the strong link between depression and panic or depression and pain, and the perhaps even 
stronger link between panic and pain.  Furthermore, the available evidence is limited to cross 
sectional studies.  Therefore, the proposed study will provide important information on how 
comorbid panic and pain symptoms affect depression treatment outcomes in a primary care 
population. 
 CHAPTER III 
A RANDOMIZED TRIAL INVESTIGATING SSRI TREATMENT (ARTIST) 
III.  A RANDOMIZED TRIAL INVESTIGATING SSRI TREATMENT (ARTIST) 
 The current study used data from ARTIST.  This section focuses on ARTIST, 
including the study design, study population, and information about the rating scales used.  It 
also provides information about prior research that utilized the ARTIST dataset (including 
the original publication). 
 
Overview of Study Design 
 ARTIST was a 9-month randomized, open-label, effectiveness clinical trial 
comparing three SSRIs: fluoxetine, paroxetine, or sertraline (n=573) in primary care using 
patients from two primary care research networks.2  The first primary care research network 
was a not-for-profit voluntary organization of more than 10,000 family practitioners, 
internists, and pediatricians throughout the country [The Primary Care Network (n=51 study 
practitioners)].  The second primary care network was an academic site management 
organization within the Duke University Health System made up of over 150 family 
physicians, internists, and pediatricians who participate in clinical outcomes trials [The Duke 
Primary Care Research Consortium (n=26 study practitioners)].   
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Study Population 
 The ARTIST study population included patients aged 18 years and over who were 
visiting network primary care doctors between April and November 1999; the visits were not 
required to be depression related.  If the patient was diagnosed with depression and the PCP 
deemed him/her appropriate for SSRI treatment, further enrollment criteria were assessed 
including access to a telephone.  Exclusion criteria included: being actively suicidal; current 
treatment or treatment within the past two months with an SSRI; taking a non-SSRI 
antidepressant either for depression or for a non-depressive disorder; active substance abuse; 
pregnant or breastfeeding; cognitive impairments (e.g., dementia or psychosis); inability to 
read, speak, or write English; or a terminal illness.  At the start of the trial, patients were 
randomly assigned to open-label treatment with one of three SSRIs (sertraline, paroxetine, 
fluoxetine). 
 A total of 601 patients provided informed consent and were randomized, 573 
completed the baseline assessments, and 455 patients (79%) completed 9 months of 
treatment.  The pre-baseline dropouts were similar to the patients who remained in the study 
except they had slightly less severe depression.2   
 
Rating Scales  
Depression measures included the PHQ-9, the SCL-20, and the Primary Care Evaluation 
of Mental Disorders (PRIME-MD) depression module.   
 In the original ARTIST study, the SCL-20 was one of the scales used to measure 
depression treatment outcome at each visit (baseline and months 1, 3, 6, and 9).114  The 
SCL-20 is a modified subscale of the Hopkins Symptom Checklist and Brief Symptom 
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Inventory and has been shown to detect differences in severity among treatment groups in 
primary care trials.115-117  The SCL-20 is made up of 20 questions about how distressed 
(“not at all”, “a little bit”, “moderately”, “quite a bit”, or “extremely”) patients were by 
various symptoms during the past 4 weeks.  The items are scored from 0 to 4 and 
averaged to provide an overall severity from 0 to 4, with a score of 4 indicating more 
severe depression.118  The scale has been used in many primary care studies and has been 
shown to have similar responsiveness to the Hamilton Depression Rating Scale and the 
Inventory of Depressive Symptomatology. 
 Other psychological measures included the three anxiety screening questions from 
the BPHQ, the PHQ-15, and the Short Form-36 (SF-36) bodily pain subscale (BPS).  
SSRI compliance, current antidepressants, reasons for antidepressant change, and adverse 
effects were assessed at each of the post-baseline visits.  The schedule of visits for 
selected study measurements relevant to the proposed analyses is provided in Table 5. 
 
Table 5.  Schedule of visits and measures for the ARTIST study through month 6 
Measure Baseline Month 1 Month 3 Month 6 
Demographics X    
Medications  X X X 
SCL-20 X X X X 
3 anxiety questions from 
BPHQ X  X  
SF-36 BPS X  X  
PHQ-15 pain scale X X X X 
 
  In addition to measures of depression, pain, and anxiety, ARTIST also captured a 
number of other covariates, including demographic and other clinical characteristics, 
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psychosocial measures, social function, work function, health-related quality of life, 
medication use, and healthcare utilization (Table 6).   
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Table 6.  Covariates captured in ARTIST 
 
Demographics and Clinical Characteristics 
 Age 
 Race 
 Sex 
 Alcohol Use/Problems with alcohol 
Psychological Measures 
 Positive well-being scale from the RAND Medical Outcomes Study (MOS) 
questionnaire 
 Hopefulness scale from the Health Outcomes Study Questionnaire 
 Somatization severity scale from the PHQ 
 Disposition (self-esteem) scale from the Health and Daily Living Form 
Social Function 
 SF-36 social functioning scale 
 Quality of Social Interaction scale 
 Quality of Close Relationships Scale 
Work Function 
 Work Limitations Questionnaire 
 Questions about work effectiveness  and impaired work functioning 
Health-related Quality of Life 
 SF-36 physical functioning scale 
 SF-36 role-physical scale 
 SF-36 bodily pain scale 
 SF-36 general health perceptions 
 SF-36 vitality scale 
 Medical Outcomes Study (MOS) concentration and memory scale 
 MOS sleep scale 
 MOS sexual functioning scale 
Medication Use 
 SSRI randomized 
 Prior Use of Antidepressants 
 SSRI compliance 
 Current antidepressant use 
 Changes in antidepressant use 
 Adverse effects 
Healthcare Utilization 
 Clinic, emergency department, and hospital use (including visits to a mental health 
professional) 
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ARTIST Results 
 Overall, the three SSRIs (fluoxetine, paroxetine, sertraline) were similar in all 
measures including improvement of depression as measured by the MCS score.2 At 
month 9, mean change from baseline in MCS scores were +15.8 for paroxetine-treated 
patients, +15.1 for fluoxetine treated patients, and +17.4 for sertraline-treated patients.  
The three treatment groups were also similar in mean change from baseline in SCL-20 
score: -0.82 for paroxetine-treated patients, -0.85 for fluoxetine treated patients, and -0.99 
for sertraline-treated patients.  Rates of depression recovery (defined by an MCS score 
greater than or equal to 40) at Month 9 were 81%, 77%, and 84% for paroxetine, 
fluoxetine, and sertraline patients, respectively.  When recovery was defined as an SCL-
20 score of 1.0 or less at Month 9, 69%, 67%, and 74% of patients, respectively, 
experienced recovery.  The treatment groups were also similar in the numbers and types 
of adverse effects reported. 
 
Response, partial response, and nonresponse in ARTIST 
 Corey-Lisle et al. evaluated response, partial response, and nonresponse after 6 
months of treatment.119  Using the reliable change index (RCI) to define a clinically 
meaningful response, SCL-20 change scores were not clinically meaningful unless the 
change was greater than or less than 12.3.119  Remission was defined as meeting the RCI 
criteria and having a score of 6 or less on the SCL-20 and partial response was defined as 
meeting the RCI criteria and experiencing a >50% change from baseline in SCL-20 score.  
Patients were considered non-responders if they did not meet the minimum RCI criteria.   
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 At month 6, using the criteria above, 109 patients (22.6%) were responders, 152 
were partial responders (31.5%) and 221 were nonresponders (45.9%).  Nonresponders 
were older than responders and partial responders; patients who responded were less 
likely to have double depression or suicidal ideation than partial responders or 
nonresponders.  Age, diagnosis, worse physical functioning, and lower energy level were 
all predictors of response.  Anxiety symptoms (symptoms of panic disorder and GAD) 
were not evaluated as potential predictors of nonresponse. 
 
Baseline pain and depression outcomes in ARTIST 
 As described briefly above (Background and Significance), Bair et al. evaluated the 
effect of pain at baseline, defined using both the SF-36 BPS and the PHQ-15 pain scale, on 
depression outcomes.104  Pain was categorized (none, mild, moderate, severe) using both the 
SF-36 and the PHQ-15.  Severity of pain, as measured by the SF-36 pain intensity items, was 
associated with baseline depression severity.  Patients with severe pain had higher SCL-20 
scores than patients with moderate or mild pain (1.91 vs. 1.76 and 1.61, respectively) while 
patients with no pain had the lowest SCL-20 scores (1.48).  Pain severity, as measured by 
both the SF-36 and the PHQ-15, was a predictor of depression outcomes in both the logistic 
regression model where depression was measured as a dichotomous outcome and in the 
linear regression model where depression outcomes was defined as a continuous variable 
(change from baseline at month 3 in SCL-20 score).  Both the logistic and linear regression 
models controlled for age, gender, race, SSRI, clinic site, treating physician, non-pain 
somatic symptoms, and baseline SCL-20 depression score; the strongest predictor was 
baseline depression severity. 
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Prevalence of physical symptoms and the outcome of physical symptoms in ARTIST  
 Greco et al. evaluated the prevalence of physical symptoms as well as the effect 
of physical symptoms on health related quality of life and the outcome of physical 
symptoms over 9 months of treatment.105  Between 30-50% of patients reported one or 
more of the 14 pain symptoms at baseline with 10-20% of patients reporting that the pain 
symptoms were severe.  Only a small percentage (<15%) of patients reported new 
physical symptoms, i.e., physical symptoms that were not present at baseline but began 
during the study.  The prevalence of pain symptoms decreased during the first month of 
treatment and then remained fairly constant from Month 1 to Month 9.   
 Patients who experienced depression remission (an SCL-20 score <0.5 after 3 
months of antidepressant treatment) or partial response (>50% improvement in SCL-20 
score with a final score >0.5) experienced greater improvements in pain symptoms than 
nonresponders (patients who had neither an SCL-20 improvement of greater than 50% 
nor an SCL-20 score less than 0.5) at Months 1 and 3 (p<0.001).  There was no difference 
in pain improvement between patients who achieved depression remission or partial 
response.  This study did not include an analysis of the effect of panic symptoms as a 
potential confounder or effect measure modification (EMM), but this was not the primary 
focus of their study.   
 The current study expanded on this research by evaluating how baseline pain and 
early improvement in pain affect depression outcomes during the maintenance phase of 
treatment (month 6).  Additionally, we explored whether panic was a confounder or 
EMM of the relationship between pain and depression outcomes.  Examining outcomes at 
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month 6 is important since this is a critical time for depression relapse, and adverse 
prognostic factors such as pain may be particularly salient in predicting relapse. 
   
CHAPTER IV 
STUDY OVERVIEW 
IV.  STUDY OVERVIEW 
 This section describes the study design and study population of the current study. 
 
Study Population 
 The study population consisted of subjects who participated in ARTIST 
(described in detail in Chapter 3).  
 Of the 573 patients randomized to treatment, 569 had information about baseline 
panic symptoms.  Over one-third (35%) of the 569 patients reported baseline panic 
symptoms (n=199) and 12% reported persistent panic symptoms (n=67)(Table 7).  
Almost all (99%) of the randomized patients had baseline pain information (n=572) and 
more than three quarters (79%) had pain symptoms (mild, moderate, or severe) (Table 7).  
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Table 7.  Prevalence of baseline panic, persistent panic, and pain  
 
 n (%) 
Panic  
Baseline panic  
 No 370 (65%) 
 Yes 199 (35%) 
 Missing 4 (<1%) 
Persistent panic  
 No 428 (75%)  
 Yes 67 (12%) 
 Missing 78 (14%) 
  
Pain  
PHQ-15 Pain   
 None 114 (20%) 
 Mild 190 (33%) 
 Moderate 165 (29%) 
 Severe 103 (18%) 
 Missing 1 (<1%) 
SF-36 Pain  
 None 114 (20%) 
 Mild 190 (33%) 
 Moderate 165 (29%) 
 Severe 103 (18%) 
 Missing 1 (<1%) 
 
Study Measures 
 We used the SCL-20, to measure depression, the three anxiety screening 
questions from the BPHQ to measure symptoms of panic disorder and GAD, and both the 
PHQ-15 pain subscale and the SF-36 BPS to measure pain.  The schedule of visits and 
study measurements relevant to the proposed analyses are provided in Table 5. 
 
Measurement of Outcome: Depression Treatment Response 
 For the proposed study, the outcome was depression treatment response, defined 
as a categorical variable (remission, partial response, and nonresponse) using the SCL-
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20.114  Remission was defined as an SCL-20 score ≤ 0.5; partial response was defined as 
≥ 50% improvement in SCL-20 score but not to a level of ≤ 0.5.  Nonresponse was 
defined as patients who do not meet either of these criteria.  Nonresponse was the referent 
level for all analyses.  The SCL-20 is described in greater detail in Chapter 3.  
 
Measurement of Exposure: Symptoms of Panic Disorder (Specific Aim 1) 
One of the exposures of interest was symptoms of panic disorder (measured at baseline 
and month 3), based on the single panic question from a three-question anxiety screening 
instrument:  
 “During the past month, have you often been bothered by… 
1. nerves or feeling anxious or on edge 
2. worrying about a lot of different things 
3. have you had an anxiety attack (suddenly feeling fear or panic)?”120   
 For the proposed analyses, participants who answered “yes” to this panic question 
(question 3 above) at baseline were considered to have symptoms of panic disorder.   
 This question has demonstrated good sensitivity and specificity in a population of 
non-depressed patients attending a clinic where the prevalence of current panic disorder 
was 8.8%.  In this study, the sensitivity and specificity (and associated 95% confidence 
intervals) were 93% (81%-99%) and 78% (74%-82%), respectively.121  Analyzing data 
from the 1000 primary care patients evaluated in the original PRIME-MD32 study where 
the prevalence of current panic disorder was 3.6%, we found similar operating 
characteristics for the panic question.  With the PCP’s diagnosis (which uses a structured 
DSM-IV based interview in the PRIME-MD Clinician Evaluation Guide) as the reference 
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standard, the sensitivity and specificity of the panic question were 100% and 91%, 
respectively.  With the mental health professional’s independent diagnosis (using the 
telephone-based SCID) as the reference standard, the sensitivity and specificity of the 
panic question were 86% and 92%, respectively.   
 
Measurement of Exposure: Symptoms of Pain (Specific Aim 2) 
 Pain was measured using the PHQ-15 at baseline and months 1, 3, and 6 and the SF-
36 at baseline and month 3.122  We focused primarily on the PHQ-15. 
 Pain, the second exposure of interest, was measured using the pain subscale of the 
PHQ-15122 at baseline and months 1, 3, and 6. The PHQ-15 evaluates 15 different physical 
symptoms including 5 specific pain symptoms (headache, back pain, limb or joint pain, 
abdominal pain, and chest pain) with each pain item scored from 0 (“not bothered at all”) to 2 
(“bothered a lot”).  Scores on the five specific pain items are summed to form a composite 
pain score (0 to 10) with higher scores indicating more pain.  A score of 0-2 indicates no 
pain, 3-4 indicates mild pain, 5-6 indicates moderate pain, and 7-10 indicates severe pain.104  
The validity of the PHQ-15 has been demonstrated in general internal medicine and family 
practice clinics as well as obstetrics-gynecology clinics.122   
 The SF-36 bodily pain subscale includes two items, which address pain severity and 
pain interference; the overall score ranges from 0 to 100 (with 100 indicating best health 
status).  The SF-BP is a validated tool that is commonly used in psychiatric research.123  For 
the current analysis, we focused on the single pain severity question.  For the purposes of this 
analysis, pain was categorized as follows: “none” or “very mild” = none, “mild” = mild, 
“moderate” = moderate, and “severe” or “very severe” = severe pain.   
 39 
 For the proposed analyses, we considered pain as a dichotomous variable (none/mild, 
moderate/severe) and a categorical variable (none, mild, moderate, or severe pain). 
 
Measurement of Exposure: Improvement in Pain (Specific Aim 3) 
 Early pain improvement was defined as ≥ 3 point change from baseline to month 
1 in the PHQ-15 pain score.122  A 3-point change was used because it reflects the mean 
change from baseline to endpoint for patients treated with extended-release venlafaxine 
in anxious and/or depressed patients with multisomatoform disorder.124  Furthermore, a 
3-point improvement in pain is approximately equal to a change in pain level when pain 
is categorized as none, mild, moderate, or severe using the PHQ-15 pain subscale.  To 
explore how sensitive the results were to our choice of pain change cut-off, we explored 
the final regression model with pain improvement defined as ≥ 2-point change in pain 
score. 
 
Covariates of Interest 
  As described in Chapter 3, ARTIST captured demographic and other clinical 
characteristics, psychological measures, social function, work function, health-related 
quality of life, medication use, and healthcare utilization.   
  For the current study, we considered age (measured at baseline), race (baseline), 
sex (baseline), SSRI randomized (baseline), prior use of an antidepressant (baseline), 
alcohol use (baseline), and problems with alcohol (baseline, months 1, 3, and 6) as 
potential confounders or effect measure modifiers (EMM). 
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  Comprehensive antidepressant information was captured (both the name of the 
medication and its dosing), including changes made to the treatment over the course of 
the study.  We evaluated adequacy of antidepressant treatment in two ways.  First, 
treatment was defined as adequate (treatment at month 6 above the usual recommended 
minimum dose [Table 8]) or inadequate (no treatment or treatment at month 6 below the 
minimum usual recommended dose) based on treatment at the month 6 visit only.  We 
also explored adequate treatment over the initial 6 months of the study.  Adequate 
treatment over 6 months was defined as treatment at each visit above the usual 
recommended dose range with no gaps in treatment greater than 2 weeks whereas 
inadequate treatment over 6 months was defined as treatment at any visit below the 
recommended dose range or intermittent treatment (gaps in treatment greater than 2 
weeks). 
Table 8.  Minimum usual antidepressant dose125 
 
Generic Name (Trade Name) Minimum Usual Daily Dose 
Amitriptyline (Elavil®) 150mg 
Bupropion (Wellbutrin®) 300mg 
Citalopram (Celexa®) 20mg 
Fluoxetine (Prozac®) 20mg 
Mirtazapine (Remeron ®) 15mg 
Nefazadone (Serzone®) 300mg 
Paroxetine (Paxil®)  20mg 
Sertraline (Zoloft®) 50mg 
Trazadone (Desyrel®) 300mg 
Venlafaxine (Effexor®) 125mg 
Abbreviations: milligrams (mg) 
 
  Because treatment of pain may affect our results, we also explored prior treatment 
with pain medications.  The pain medications reported at baseline included: non-steroidal 
anti-inflammatory drugs (ibuprofen, naproxen, Piroxicam®, Celebrex®, Vioxx®, 
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Voltaren®, Lodine®, Relafen®, Daypro®), Tylenol®, aspirin, migraine/tension headache 
medications (Midrin®, Imitrex®), arthritis medications (Enbrel®), and other pain 
medications and muscle relaxants (including Ultram®, Vicodin®, Percocet®, Robaxin®, 
Valium®, Flexeril®, Skelaxin®, Soma®, Lortab®, Oxycontin®, MS Contin®, Fioricet®, 
Tylenol #3 with Codeine® and Tylox®).  No information about pain medication over the 
course of the study was available. 
  Additionally, symptoms of panic disorder was considered a potential confounder 
or EMM for specific aims 2 and 3.  We also controlled for baseline pain severity 
(measured as a continuous covariate) for specific aim 3, because we were exploring 
improvement in pain based on a change score (baseline to month 1).   
   All models included baseline depression severity.   
Data Acquisition 
 Permission to use the ARTIST data was obtained from Dr. Ralph Swindle, Senior 
Research Scientist in Outcomes Research at Eli Lilly and Company and Dr. Kurt 
Kroenke, Research Scientist at The Regenstrief Institute and Professor of Medicine at 
Indiana University School of Medicine.   
  
CHAPTER V 
DATA ANALYSIS METHODS 
V.  DATA ANALYSIS METHODS 
Data Transformations and Basic Analysis Methods 
 To ensure accurate characterization of the relationships, we began with 
exploratory analysis and univariate descriptive analysis before progressing to 
multivariate analysis.  All analyses were completed using SAS version 9.1 (SAS 
Institute, Cary, NC). 
 Because the continuous variables appeared to be normally distributed and 
linear in the logit, no transformations were applied nor were any continuous variables 
recoded into indicator variables to meet the assumptions of statistical tests applied to 
the data. 
 
Common Analysis Approach to Specific Aims 1, 2, and 3  
Definition of Depression Treatment Response  
 As described above, the primary outcome of interest for all analyses was 
depression treatment response (remission, partial response, nonresponse).  Remission 
was defined as an SCL-20 score ≤ 0.5; partial response was defined as ≥ 50% 
improvement in SCL-20 score but not to a level of ≤ 0.5.  Nonresponse was defined 
as patients who do not meet either of these criteria.  
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 A new variable was created for the three level outcome, depression treatment 
response, from the original ARTIST variable (Table 9) 
Table 9.  Variable coding (depression outcome) 
Name Variable Description Variable 
type 
Coding 
DEPRESS 
 
Outcome: Remission from 
depression  
Categorical 0=no remission 
1=partial response 
2=remission 
 
Analyses to Address Specific Aim 1 
 Specific Aim #1: To determine the effect of panic symptoms on the outcomes for 
treatment of depression at month 6.  Hypothesis: Depressed patients with panic 
symptoms will have worse outcomes than depressed patients without panic symptoms.  
 
Variable Recoding 
 To address specific Aim #1, we created a new variable for the main exposures 
of interest, symptoms of panic disorder at baseline and persistent panic (panic at 
baseline and month 3) (Table 10). 
Table 10.  Variable coding (panic) 
Name Variable Description Variable type Coding 
PANIC_0 Exposure: self-reported panic 
symptoms at baseline 
Binary  0=no  
1=yes 
PER_PANIC Exposure: self-reported panic 
symptoms at baseline and month 3 
Binary 0=no  
1=yes 
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Statistical Analysis 
Exploratory Analysis 
 First, we examined the univariate distribution of both the outcome (depression 
treatment response at month 6) and the exposure (panic symptoms).  This included 
the percentage in each category (including missing values).  We also examined the 
distributions of each of the categorical covariates (including the frequency 
distribution and missingness) and the univariate distributions (including normality 
distribution, skew, kurtosis, outliers, and missingness) for each of the continuous 
covariates.   
 If there was more than 5% missing for any variable (outcome, exposure, or 
covariate) we examined whether the missingness was associated with the other 
variables (outcome, exposure, or covariates, as appropriate).  For categorical 
covariates, we calculated an odds ratio (OR) that explores the level of missingness at 
each level of the other variable; a strong association of the missingness was defined 
as an OR ≥ 3.0 or ≤ 0.3.  For continuous covariates, we examined whether the 
missingness was associated with continuous covariates by exploring the mean, 
standard deviation, minimum, and maximum at each level of missingness (missing vs. 
not missing).  This information was used to determine if the missingness was missing 
at random, missing completely at random, or not missing at random. 
Effect Measure Modification  
 To determine whether there was EMM, we constructed a multinomial logistic 
regression model that included the exposure, the potential EMM, and the interaction 
term and we assessed the interaction term for confounding (see below). To assess 
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EMM, we compared the ORs and likelihood scores for the full model (the model with 
the interaction term) and the reduced model (the model without the interaction term).  
Covariates with a significant likelihood ratio test (P < 0.20) with an adequate sample 
size to explore an interaction (>10 in each cell) were considered EMMs. 
Confounding 
 First, we examined whether each of the potential confounders (i.e., covariates 
that are not strong EMM) was correlated with the main exposure (baseline or 
persistent panic symptoms).  To assess confounding in all of the regression models 
we used a change in estimate approach.  A covariate was considered a confounder if 
the adjusted estimate was greater than 10% different from the unadjusted estimate.   
 Because we had a three level outcome, a covariate was considered a 
confounder if the adjusted estimate was greater than 10% different from the 
unadjusted estimate in either comparison (remission vs. nonresponse or partial 
response vs. nonresponse). 
Logistic Regression Modeling 
 As the outcome of interest, depression treatment response, was a three level 
categorical variable (remission, partial response, nonresponse), we used multinomial 
logistic regression.  
Model 1 
 We used multinomial logistic regression (model 1) to explore the effect of 
baseline and persistent panic symptoms on depression treatment outcomes at month 6. 
 Model 1: Logit (DEPRESS) = β0 + β1 * PANIC + β2 * SCL-20baseline + error 
Where panic is baseline panic or persistent panic depending on the analysis. 
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 For this model (model 1), we explored the following covariates:  
• Age (baseline) 
• Race (baseline) 
• Sex (baseline) 
• SSRI randomized (baseline) 
• Use of antidepressants prior to current diagnosis (baseline) 
• Problems with alcohol (baseline) 
• Adequacy of antidepressant treatment (over 6 months of treatment and at 
the 6 month visit) 
Model building strategy - Model 1 
 The model-building strategy was backward elimination, which allowed us to look 
at the effect of each covariate in the presence of the other variables.  The model-building 
steps were: 
1. All potential effect measure modifiers were evaluated by running a model with the 
main exposure, the potential effect measure modifier, and the interaction term in SAS 
(proc logistic, glogit link) and using a likelihood ratio test (see above).  
2. A full model (including the main exposure, all possible covariate confounders, and 
the interaction terms, if any) was run in SAS (proc logistic, glogit link). 
3. All covariates (including the main exposure of interest) and interaction terms (see 
step 1 above) were assessed for confounding using a change-in-estimate approach. 
a. The OR for the main exposure, adjusting for all covariates (including 
interaction terms) was calculated from the full model (ORfull). 
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b. The covariate that was least likely to change the relationship between the 
exposure and the outcome was identified by determining which covariate has 
the highest p-value in the full model. 
c. The covariate with the highest p-value was removed and an OR for the 
relationship between the exposure and the outcome was calculated (ORreduced). 
d. The two ORs were compared using the following formula: 
ln|ORfull/ORreduced| 
within each strata of the effect measure modifier if any interaction term were 
retained (see step 1 above). 
e. Steps b-d were repeated for each covariate in the model, building on the prior 
steps (i.e., the retention/removal of variables). 
f. The final model included all retained variables. 
Missing Data  
 The effect of missing data was explored using last observation carried forward 
and multiple imputation analyses.  For the last observation carried forward analysis, 
the last observed SCL-20 score was carried forward and used to create the outcome 
variable (depression outcome defined as remission, partial response, or nonresponse).  
For the multiple imputation analysis, we imputed missing values for the month 6 
SCL-20 score.  The imputation algorithm included age, race, gender, problems with 
alcohol, alcohol use, SCL-20 score (months 1, 3, and 6), adequacy of depression 
treatment, and type of depression.  After imputation of the SCL-20 score at month 6 
using SAS PROC MI, we created the outcome variable (depression treatment 
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outcome at month 6 defined as remission, partial response, and nonresponse) and 
used SAS PROC LOGISTIC and SAS PROC MIANALYZE to generate the 
multinomial logistic regression parameter estimates and associated standard errors. 
 
Sensitivity Analysis  
 Because one of the main exposures of interest, symptoms of panic disorder, was 
self-reported using a 3-item anxiety-screening instrument rather than a clinical diagnosis, 
there is possibility that panic disorder was misclassified.  Even though panic disorder was 
classified as a dichotomous variable and the expected direction of bias is towards the 
null, there have been instances where this assumption is incorrect.  Despite the fact that 
the bias might be toward the null, i.e., conservative, this is still an incorrect inference.  
We used a probabilistic sensitivity analysis that allowed us to quantify, in addition to 
random error, the magnitude and direction of systematic error.   
 Probabilistic sensitivity analysis uses Monte Carlo techniques to simulate, based 
on a range of postulated sensitivity and specificity estimates, what would have been the 
observed data had misclassification not occurred.  The technique is described in detail by 
Fox and Lash [Int J Epid] and a SAS macro was developed by Lash and Fink that is 
available on the web.126, 127  We used this macro to assess the effect of varying the 
sensitivity and specificity of the three anxiety questions, with specific focus on the panic 
question.  The macro provided a median estimate of the measure of association along 
with three 95% confidence intervals, an interval for: random error only, systematic error 
only, and one that accounts for both random and systematic error.  
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 The range of sensitivity and specificity explored was determined using published 
data about the sensitivity/specificity of the panic question.121, 128  We varied both the 
sensitivity and the specificity of the panic question from a low of 60% to a high of 100%.  
 We specified a trapezoidal density function, which is described by Fox et al. as 
“the simplest realistic density function” which is specified by four points: the lower and 
upper bounds and the lower and upper modes.127  Between the upper and lower modes the 
density is flat and equal to the modes; “this flat region is the zone of indifference.”  The 
minimum was set to 60%, mode 1 to 75%, mode 2 to 90%, and the max to 100%.   
 
Analyses to Address Specific Aim 2 
 Specific Aim #2: To determine the effect of baseline pain symptoms on 
depression treatment outcomes at month 6.  Hypothesis 2: Depressed patients with 
baseline pain symptoms will have worse outcomes than depressed patients without 
baseline pain symptoms. 
 To address specific Aim #2, we created new variables for pain symptoms at 
baseline (Table 11).   
Table 11.  Variable coding (pain) 
Name Variable Description Variable type Coding 
Pain_sev_0 Self-reported pain at 
baseline 
Categorical 0=no pain 
1=mild pain 
2=moderate pain 
3=severe pain 
Any_Pain_0 Self reported pain at 
baseline 
Binary 0=no/mild pain 
1=moderate/severe pain 
 
 The analyses began with the dichotomous pain variable, which allowed us to 
evaluate depression treatment outcomes for patients with moderate/severe pain vs. 
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no/mild pain.  We also explored the interaction between pain and panic.  Because 
there was no interaction of pain and panic, we explored the effect of baseline pain on 
depression treatment outcomes using the 4-level categorical variable. 
 
Statistical Analysis 
Exploratory Analysis 
 As in specific aim 1, we examined the univariate distribution of the outcome 
(depression treatment response at month 6) and the exposure (baseline pain 
symptoms), the distributions of each of the categorical covariates, and the univariate 
distributions for each of the continuous covariates.   
 As described in Specific Aim 1, if there was more than 5% missing for any 
variable (outcome, exposure, or covariate) we examined whether the missingness was 
associated with the other variables (outcome, exposure, or covariates, as appropriate).  
For categorical covariates, we examined odds ratios; for continuous covariates, we 
explored the mean, standard deviation, minimum, and maximum at each level of 
missingness (missing vs. not missing).   
Effect Measure Modification and Confounding 
 EMM and Confounding was assessed using the methods described for 
Specific Aim 1.  
Logistic Regression Modeling 
 As in Specific Aim 1, the outcome of interest, depression treatment response 
was a three level categorical variable (remission, partial response, nonresponse); 
therefore, we used multinomial logistic regression. 
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Model 2 
 We used multinomial logistic regression model (model 2) to explore the effect 
of baseline pain on depression treatment outcomes at month 6.  
 Model 2: Logit (DEPRESS) = β0 + β1 * PAIN + β2 * SCL-20baseline + error 
 For this model, we explored the following covariates:  
• Age (baseline) 
• Race (baseline) 
• Sex (baseline)  
• SSRI randomized (baseline)  
• Use of antidepressants prior to current diagnosis (baseline) 
• Problems with alcohol (baseline) 
• Symptoms of panic (baseline) 
• Adequacy of antidepressant treatment 
• Concomitant pain medication (baseline) 
Model building strategy - Model 2 
 The model-building strategy was backward elimination, which allowed us to look 
at the effect of each covariate in the presence of the other variables.  The model-building 
steps were the same as described for Specific Aim 1.  
Missing Data  
 As described for Specific Aim 1, we first used a complete case analysis, 
followed by a LOCF analysis, and an analysis using multiple imputation. 
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Sensitivity Analysis 
 If panic was retained in the model (after assessment of confounding and 
EMM), we conducted a probabilistic sensitivity analysis (described in detail in for 
Specific Aim 1). 
 
Analyses to Address Specific Aim 3 
 Specific Aim 3: To determine the effect of early improvement in pain (baseline to 
month 1) on depression treatment outcomes at months 1 and 6.  Hypothesis 3: Depressed 
patients without early improvement in pain will have worse outcomes at months 1 and 6 
than depressed patients with early improvement in pain. 
 To address specific Aim #3, we created new variables for the improvement of 
pain (early pain improvement).  This variable was created by taking the difference in the 
pain score (measured as a continuous variable) from baseline to month 1 (Table 12).  If a 
patient had at least a three point improvement in pain score they were deemed to have 
early pain improvement.  All analyses were repeated using a 2-point change in pain score. 
Table 12.  Variable coding (early pain improvement) 
Name Variable Description Variable 
type 
Coding 
Early_improve3 Exposure: early 
improvement in pain 
(improvement from 
baseline to month 1) 
Categorical 1= ≥ 3 point change 
0= < 3 point change  
Early_improve2 Exposure: early 
improvement in pain 
(improvement from 
baseline to month 1) 
Categorical 1= ≥ 2 point change 
0= < 2 point change 
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Statistical Analysis 
Exploratory Analysis 
 As in specific aim 1, we examined the univariate distribution of the outcome 
(depression treatment response at month 6) and the exposure (early pain 
improvement), the distributions of each of the categorical covariates, and the 
univariate distributions for each of the continuous covariates.   
 If there was more than 5% missing for any variable (outcome, exposure, or 
covariate) we examined whether the missingness was associated with the other 
variables (outcome, exposure, or covariates, as appropriate) (described in detail for 
specific aim 1).  For categorical covariates, we examined odds ratios; for continuous 
covariates, we explored the mean, standard deviation, minimum, and maximum at 
each level of missingness (missing vs. not missing) for continuous covariates.   
Effect Measure Modification and Confounding 
 EMM and Confounding was assessed using the methods described for 
Specific Aim 1.   
Logistic Regression Modeling 
 As in Specific Aim 1, the outcome of interest, depression treatment response, 
was a three level categorical variable (remission, partial response, nonresponse) we 
used multinomial logistic regression. 
Model 3 
 We used multinomial logistic regression model (model 3) to explore the effect 
of early pain improvement on depression treatment outcomes.    
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Model 3:  
Logit (DEPRESS) = 
     β0 + β1*EARLY PAIN IMPROVE + β2*SCL-20baseline + β3*PHQ-15baseline + error 
 For this model, we explored the following covariates:  
• Age (baseline) 
• Race (baseline) 
• Sex (baseline)  
• SSRI randomized (baseline)  
• Use of antidepressants prior to current diagnosis (baseline) 
• Problems with alcohol (baseline) 
• Symptoms of panic (baseline) 
• Adequacy of antidepressant treatment 
• Concomitant pain medication (baseline) 
Model building strategy - Model 3 
 The model-building strategy was backward elimination, which allows us to look 
at the effect of each covariate in the presence of the other variables.  The model-building 
steps were the same as described for Specific Aim 1.  
Missing Data  
 As described for Specific Aim 1, we first used a complete case analysis, 
followed by a LOCF analysis, and an analysis using multiple imputation. 
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Statistical Power 
 Approximately 30% of patients treated for depression with an SSRI in 
primary care achieve remission of symptoms after initial treatment with an SSRI.129 
In ARTIST, 22% of patients experienced remission at month 6; we estimated that 
patients without panic/pain and those with improvement in pain would have a higher 
rate of remission (40%).  Given the literature and the results from ARTIST, we 
examined the power of this study to detect a range of plausible ORs for depression 
remission.  We are only presenting the power calculations for remission vs. 
nonresponse; because fewer patients were expected to achieve remission as compared 
to partial response, the remission analyses will have less power than the partial 
response analyses.  
 We had the following power for a two-sided alpha=0.05 for each “exposure” 
(panic/pain, early improvement in pain): 1) given 385 participants with complete data 
available for analysis and a 34% prevalence of baseline panic symptoms at baseline, 
we had approximately 80% power to detect an OR = 0.70 for the effect of panic 
symptoms on remission from depression; 2) given 365 participants with complete 
data available for analysis and a 12% prevalence of persistent panic, we had 80% 
power to detect an OR = 0.56 for the effect of persistent panic symptoms on 
remission from depression; 3) given 336 participants with complete data available for 
analysis and a 80% prevalence of pain symptoms at baseline, we had 80% power to 
detect an OR = 0.73 for the effect of pain symptoms on remission from depression; 4) 
given 482 participants with complete data available for analysis and a 27% 
prevalence of early pain improvement, we had 80% power to detect an OR = 1.44 
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for the effect of early improvement in pain symptoms on remission from depression 
at month 6. Adjustment for confounding will diminish statistical power somewhat; 
however, preliminary results suggest that the covariates are relatively balanced 
between the exposure groups.  Missing data will also diminish statistical power 
somewhat. 
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Abstract 
Background: Comorbid panic symptoms may complicate depression treatment.  However, 
most research focuses on specialty care, and the evidence in primary care is mixed. 
Methods: We analyzed data from A Randomized Trial Investigating Selective Serotonin 
Reuptake Inhibitor (SSRI) Treatment, a longitudinal effectiveness study comparing 3 SSRIs 
for the treatment of depression in primary care (n=573).  Depression at month 6 was 
measured using the Symptom Checklist-20; remission was defined as a score ≤ 0.5; partial 
response was defined as ≥ 50% improvement but not to a level of ≤ 0.5.  Nonresponse, the 
referent level for all analyses, was defined as patients who do not meet either of these 
criteria.  Panic symptoms (yes/no) were measured using a screening question. 
Results: Rates of remission vs. nonresponse [OR=1.06 (95% confidence interval 0.67, 1.67)] 
or partial response vs. nonresponse [OR=0.92 (95% CI 0.54, 1.57)] were similar among 
patients with baseline panic symptoms, adjusting for baseline depression severity.  Patients 
with persistent panic symptoms were less likely to experience remission (OR=0.38, 95% CI 
0.18, 0.81) or partial response (0.66, 95% CI 0.33, 1.33).  Results were similar using 
complete case, last observation carried forward, and multiple imputation methods, and were 
robust to varying the sensitivity and specificity of the panic screening question.   
Conclusion: Panic symptoms that persist are associated with worse depression outcomes in 
the maintenance phase.  Consequently, improvement in panic symptoms may be important 
for improved depression outcomes and primary care physicians should be attuned to the 
presence of panic symptoms when making treatment decisions. 
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Introduction 
 Depression is a common and debilitating illness that is often treated in a primary care 
setting.4, 5  Though depression seen in primary care is often thought to be less severe,24-26 a 
direct comparison of the two treatment settings revealed that severity of depression was 
similar among patients treated in primary vs. specialty care.27, 28  Regardless of treatment 
setting, the goal of depression treatment is remission, or absence of depressive symptoms.  
However, a large “real world” antidepressant effectiveness trial demonstrated that only about 
30% of patients experience remission, with similar remission rates for primary vs. specialty 
care.1  With remission as the goal of depression treatment, understanding the factors that may 
influence treatment outcomes, such as comorbid panic symptoms, is critical.  
 Like depression, anxiety symptoms and anxiety disorders [e.g., generalized 
anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, 
posttraumatic stress disorder (PTSD), and social anxiety disorder (SAD)] are common in 
the primary care setting.130  Furthermore, comorbid anxiety symptoms and anxiety 
disorders are common in depressed patients.  In the National Comorbidity Survey (NCS) 
and NCS-Replication almost 60% of patients with lifetime major depressive disorder 
(MDD) had a comorbid anxiety disorder with even more patients experiencing comorbid 
anxiety symptoms.13  In the STAR*D study, which compared depression outcomes in 
primary and specialty care, depression with comorbid anxiety was significantly more 
common in primary vs. specialty care, even after adjusting for baseline depression 
severity.14, 15  The most common anxiety disorders in primary care are GAD and SAD,29, 
30
 although many depressed patients treated in primary care suffer from comorbid panic 
disorder.  Panic disorder is associated with severe disability and work impairment in 
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patients treated in primary care, even when controlling for the presence of physical and 
depressive illness.131 
 In a primary care setting, comorbid panic attacks and panic disorder are 
associated with more severe depressive illness and greater disability.61, 64  Similarly, some 
studies have found that a lifetime history of panic disorder is associated with more severe 
depression,62 greater impairment,62 and poorer treatment response.55, 62, 63  However, other 
studies have not confirmed this, finding instead that the presence of comorbid panic does 
not affect treatment outcomes64, persistence of depression, 65  or quality of life.132  In light 
of the mixed evidence, the high prevalence of comorbid anxiety in depressed patients, 
and the clinical importance of panic disorder, it is important to understand how comorbid 
panic affects depression outcomes, particularly in primary care patients.    Thus, our 
research question was: for depressed primary care patients, do baseline panic symptoms 
or persistent panic symptoms affect treatment outcomes at 6 months?  
 
Methods 
Design and Setting 
 ARTIST (A Randomized Trial Investigating SSRI Treatment) was a 9-month 
randomized, open-label, effectiveness trial comparing three selective serotonin reuptake 
inhibitors (SSRIs) using patients from two primary care research networks.2  The first 
primary care research network was a not-for-profit voluntary organization of more than 
10,000 family practitioners, internists, and pediatricians [The Primary Care Network (n=51 
study practitioners)].  The second primary care network was an academic site management 
organization within the Duke University Health System made up of over 150 family 
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physicians, internists, and pediatricians who participate in clinical outcomes trials [The Duke 
Primary Care Research Consortium (n=26 study practitioners)]. 
Study Population 
 The ARTIST study population included patients aged 18 years and over who were 
visiting network primary care doctors between April and November 1999; the visits were not 
required to be depression related.  Patients were eligible if they received their primary care 
from a participating physician, were over 18 years of age, had a depression diagnosis that 
was deemed appropriate for SSRI treatment, and had access to a telephone.  Exclusion 
criteria included: suicidal ideation; SSRI treatment currently or within the past 2 months; 
current non-SSRI antidepressant use either for depression (any dose level) or for a non-
depressive disorder (at more than low doses, e.g. >50mg of amitriptyline or its equivalent); 
active substance abuse; pregnancy or breastfeeding; cognitive impairments (e.g., dementia or 
psychosis); inability to read, speak, or write English; or a terminal illness.  At the start of the 
trial, patients were randomly assigned to open-label treatment with one of three SSRIs 
(fluoxetine, paroxetine, sertraline). 
Study Measures 
Outcome 
 Outcomes were assessed using a Computer Assisted Telephone Interview (CATI) 
at baseline, and months 1, 3, 6, and 9.2  Presence of depression was assessed using the 
Primary Care Evaluation of Mental Disorders (PRIME-MD) depression module.128  The 
PRIME-MD is a screening instrument designed for use in a primary care setting for the 
diagnosis of specific mental disorders using criteria from the Diagnostic and Statistical 
Manual III – Revised (DSM-III-R) and DSM-IV.128  Depression severity was assessed 
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using the Symptom Checklist-20 (SCL-20), a modified subscale of the Hopkins Symptom 
Checklist and Brief Symptom Inventory, which has been shown to detect differences in 
severity among treatment groups in primary care trials.115-117  The SCL-20 is scored from 
0 to 4, with a higher score indicating more severe depression.  Our primary outcome was 
depression response at the month 6 visit, categorized as remission, partial response, and 
nonresponse.  Remission was defined as an SCL-20 score ≤ 0.5; partial response was 
defined as ≥ 50% improvement in SCL-20 score but not to a level of ≤ 0.5.  Nonresponse 
was defined as patients who do not meet either the remission or partial response criteria. 
Exposure 
 Symptoms of panic disorder (yes/no) were assessed at baseline and month 3 using 
one question from the PRIME-MD [“During the past 4 weeks, have you had an anxiety 
attack (suddenly feeling fear or panic)?”]120  This question has demonstrated good 
sensitivity and specificity in a population of non-depressed patients attending a clinic 
where the prevalence of current panic disorder was 8.8%.  In this setting, the sensitivity 
and specificity (and associated 95% confidence intervals) were 93% (81%-99%) and 78% 
(74%-82%), respectively.121  Analyzing data from the 1000 primary care patients 
evaluated in the original PRIME-MD32 study where the prevalence of current panic 
disorder was 3.6%, we found similar operating characteristics for the panic question.  
With the PCP’s diagnosis (which uses a structured DSM-IV based interview in the 
PRIME-MD Clinician Evaluation Guide) as the reference standard, the sensitivity and 
specificity of the panic question were 100% and 91%, respectively.  With the mental 
health professional’s independent diagnosis (using the telephone-based SCID) as the 
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reference standard, the sensitivity and specificity of the panic question were 86% and 
92%, respectively.   
Additional Demographic and Clinical Characteristics  
  ARTIST captured demographic and additional clinical characteristics (e.g., prior 
treatment for depression, alcohol use), psychological measures, social functioning, work 
functioning, health-related quality of life, medication use, and healthcare utilization.  Of 
particular interest in the current study are demographic characteristics (age, race, sex.) 
and clinical characteristics [type of depression, initial SSRI (paroxetine, sertraline, 
fluoxetine), prior use of antidepressants, baseline problems with alcohol, baseline 
depression severity, and symptoms of GAD].  For the purposes of this analysis, 
race/ethnicity was defined as white vs. other.   
  Comprehensive antidepressant information was captured (both the name of the 
medication and its dosing), including changes made to the treatment over the course of 
the study.  We evaluated adequacy of antidepressant treatment in two ways.  First, 
treatment was defined as adequate (treatment at month 6 within the usual recommended 
dose range [Table 1]) or inadequate (no treatment or treatment at month 6 below the 
minimum usual recommended dose) based on treatment at the month 6 visit only.  We 
also explored adequate treatment over the initial 6 months of the study.  Adequate 
treatment over 6 months was defined as treatment at each visit within the usual 
recommended dose range with no gaps in treatment greater than 2 weeks whereas 
inadequate treatment over 6 months was defined as treatment at any visit below the 
recommended dose range (Table 1) or intermittent treatment (gaps in treatment greater 
than 2 weeks). 
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Statistical Analysis 
 We used multinomial logistic regression to assess the effects of panic symptoms 
on depression outcomes at month 6 where outcome was defined as remission, partial 
response, or nonresponse; nonresponse was the referent for all analyses.  The final 
models were constructed using a manual backward elimination change in estimate 
procedure, allowing us to explore the effects of each covariate in the presence of the other 
covariates.  The final models included the exposure of interest as well as any covariates 
that changed the odds ratio (OR) by greater than 10% for either comparison (remission 
vs. nonresponse; partial response vs. nonresponse).  To assess effect measure 
modification, we compared the ORs and likelihood scores for the full model (the model 
with the interaction term) and the reduced model (the model without the interaction 
term).  Covariates with a significant likelihood ratio test (P < 0.20) with an adequate 
sample size to explore an interaction (>10 in each cell) were considered effect measure 
modifiers.  Baseline depression severity was included as a covariate in all regression 
models.  Initial analyses included only those patients with complete data (complete case 
analysis).   
 The effect of missing data was explored using last observation carried forward 
and multiple imputation analyses.  For the last observation carried forward analysis, the 
last observed SCL-20 score was carried forward and used to create the outcome variable 
(depression outcome defined as remission, partial response, or nonresponse).  For the 
multiple imputation analysis, we imputed missing values for the month 6 SCL-20 score.  
The imputation algorithm included age, race, gender, problems with alcohol, alcohol use, 
SCL-20 score (months 1, 3, and 6), adequacy of depression treatment, and type of 
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depression.  After imputation of the SCL-20 score at month 6 using SAS PROC MI, we 
created the outcome variable (depression treatment outcome at month 6 defined as 
remission, partial response, and nonresponse) and used SAS PROC LOGISTIC and SAS 
PROC MIANALYZE to generate the multinomial logistic regression parameter estimates 
and associated standard errors. 
 All analyses (including the sensitivity analysis described in greater detail below) 
were run in SAS version 9.1.3 (SAS Institute, Cary, NC). 
Sensitivity Analysis 
 Because the exposure of interest, symptoms of panic disorder, was self-reported using 
a single dichotomous question from a 3-item anxiety-screening instrument rather than from a 
clinical diagnosis, there is a possibility that panic disorder was misclassified.  Although the 
expected direction of bias is towards the null, there may be instances where this assumption 
is incorrect leading to an inaccurate inference.  Therefore, we used a probabilistic sensitivity 
analysis that allowed us to quantify, in addition to random error, the magnitude and direction 
of potential systematic error for each logistic regression model (remission vs. nonresponse 
and partial response vs. nonresponse). 
 Probabilistic sensitivity analysis uses Monte Carlo techniques to simulate, based on a 
range of postulated sensitivity and specificity estimates, what the observed data would have 
been had misclassification not occurred.  The technique is described in detail by Fox and 
Lash [Int J Epid] and a SAS macro was developed by Lash and Fink.126, 127  The macro 
provides a median estimate of the measure of association along with three 95% confidence 
intervals: random error only, systematic error only, and one that accounts for both random 
and systematic error.   
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 The range of sensitivity and specificity for the sensitivity analysis was determined 
using published121 data (as well as previously unpublished data from the original PRIME-MD 
study analyzed for the current paper128) regarding the sensitivity/specificity of the panic 
question, along with evaluation of plausible values.  We varied both the sensitivity and the 
specificity of the panic question from a minimum of 60% to a high of 100% (mode 1: 75%, 
mode 2: 90%). 
 
Results 
 A total of 601 patients provided informed consent and were randomized to treatment, 
573 completed the baseline assessments and 482 (84%) completed assessment at 6 months 
(Figure 1).  The mean age was 46 years; most patients were women (79%) and white (84%).  
Of the 573 patients randomized to treatment, 569 had information about baseline panic 
symptoms and 35% of those patients reported baseline panic symptoms (n=199, Table 2); 
12% of patients reported panic symptoms at both the baseline and month 3 visits.  
 Several baseline and other clinical characteristics differed between patients with and 
without panic at baseline.  Patients with baseline symptoms of panic disorder were younger 
[43.1 years (SD=14.2) vs. 47.7 (SD=16.5)], had greater baseline SCL-20 depression severity 
[1.94 (SD=0.67) vs. 1.51 (SD=0.72)], and were less likely to have a diagnosis of minor 
depression.  They were more likely to have: a diagnosis of double depression (major 
depression with dysthymia), prior antidepressant treatment, and suicidal ideation in the past 2 
weeks.  More patients with baseline panic symptoms received adequate treatment over the 
initial 6 months of treatment (77.4% vs. 67.3 %) and at the month 6 visit (81.2% vs. 72.0%).   
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Baseline Panic Symptoms 
 The unadjusted ORs revealed no difference in either remission or partial response 
compared with nonresponse after 6 months of treatment (Table 3).  With adjustment for 
baseline depression severity, baseline panic was not associated with depression treatment 
outcomes at month 6 (remission vs. nonresponse OR=1.06, 95% CI 0.67, 1.67; partial 
response vs. nonresponse OR=0.92, 95% CI 0.54, 1.57) (Table 4).  Results were similar in 
the LOCF and MI analyses.  The results of the SA are similar; however, there is a loss of 
precision in the SA analysis compared to the CC, LOCF, and MI analyses.   
Persistent Panic Symptoms 
 Though baseline panic was not associated with worse depression outcomes, patients 
with persistent panic symptoms (panic symptoms at both baseline and month 3) were less 
likely to experience remission at month 6 in the bivariate analysis (OR=0.28, 95% CI 0.14, 
0.60, Table 5).  Similar results were seen in the multivariate model which adjusted for 
baseline depression severity (OR=0.38, 95% CI 0.18, 0.81, Table 6).  There is a weaker 
relationship in the partial response vs. nonresponse comparison (OR=0.66, 95% CI 0.33, 
1.33), suggesting an incremental response.  Results were similar for the CC, LOCF, and MI 
analyses.  Results were similar in the SA, though there was evidence of a slightly stronger 
association between persistent panic and depression remission (OR=0.15, 95% CI 0.02, 
0.54); the results are less precise in the SA vs. the CC, LOCF, and MI analyses.   
Subgroup Analysis 
 Two additional subgroup analyses were conducted.  The first subgroup analysis 
included only those patients with a diagnosis of major depression.  ARTIST included patients 
who the primary care physician had deemed sufficiently depressed to warrant treatment with 
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an SSRI, but there was no entry criterion for depression diagnosis.  Though the majority of 
patients in the ARTIST study had a diagnosis of major depression with or without dysthymia 
(73%), the study population also included patients with other depression diagnoses such as 
minor depression.  Because the severity of depression could affect our results, we evaluated 
the effect of baseline panic (n=351) and persistent panic (n=330) symptoms in those patients 
with major depression.  Among patients with MDD and baseline panic, results were similar 
to those seen in the overall study population; the odds of remission vs. nonresponse was 0.85 
(95% CI 0.51, 1.44) and the odds of partial response vs. nonresponse was 0.85 (95% CI 0.50, 
1.47) in the CC analysis.  For persistent panic, the results in the subset with MDD were also 
similar to those seen in the overall population [remission vs. nonresponse OR=0.38 (95% CI 
0.17, 0.83); partial response vs. nonresponse, OR=0.61 (95%CI 0.30, 1.22)].  Results were 
similar using LOCF, MI, and SA (results not shown).   
 The second subgroup analysis included only those patients with baseline GAD 
symptoms, which were reported by 95% of the study sample.  As expected, results in this 
subgroup were similar to those seen with the full study sample (results not shown). 
 
Discussion 
 Although baseline panic symptoms did not affect depression outcomes at 6 months, 
patients with persistent panic symptoms (panic symptoms at baseline and month 3) were 
much less likely to achieve remission at month 6.  The adverse effect of persistent panic 
symptoms on partial response is less than the effect on remission, consistent with an 
incremental or graded response.  Though our study included a heterogeneous group of 
depressed patients with a variety of depression diagnoses (double depression, major 
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depression, minor depression, dysthymia etc.), results were similar in the subgroup of 
patients with major depression (with or without dysthymia). 
 Similar to our results, prior research of depression and comorbid panic has 
consistently shown that baseline panic symptoms are associated with greater baseline 
depression severity.61, 62, 64, 65  However, research has been inconclusive with respect to the 
effect of baseline panic on depression treatment outcomes.  Some prior research in primary 
care settings has demonstrated that the presence of a lifetime or current history of panic 
attacks or panic disorder is associated with worse depression outcomes including longer time 
to recovery,55, 61-63 other studies suggest that panic disorder is not a significant predictor of 
depression outcomes.64, 65  However, like the current study, these studies, which failed to 
demonstrate an association based the presence of panic disorder on screening questions, 
rather than a clinical diagnosis, which may account for the varied results. 
 To assess how misclassification of panic symptoms due to the use of the panic 
screening question would affect our results, we conducted a probabilistic sensitivity analysis.  
The single panic screening question has demonstrated excellent sensitivity and specificity in 
non-depressed primary care samples, both in a published study121 and in our secondary 
analysis of data from the original PRIME-MD study.128  While the current analyses 
demonstrated some variability in the results of the sensitivity analysis compared to the CC, 
LOCF, and MI analyses, including a loss of precision in the estimates, overall, the results are 
robust to varying sensitivity and specificity within a large range of plausible values.   
 It is also important to consider how the use of a screening question may effect our 
definition of persistent panic symptoms.  Because we used a screening question to assess 
panic symptoms, persistent panic may result in poorer depression outcomes because it 
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represents more severe or unremitting panic symptoms, or it may simply be a better indicator 
of the presence of panic disorder than baseline panic symptoms alone.  Despite the use of a 
screening question, our results appear to be consistent with the finding by Davidson and 
colleagues that early resolution of anxiety symptoms (defined by psychic anxiety on the 
Hamilton rating scale for depression) may be a predictor of depression remission.  Moreover, 
our study conducted in primary care complements that by Davidson et al in which patients 
were treated in a specialty care setting.133   
 There was some evidence of differential treatment patterns by baseline panic 
symptoms in our study.  Patients with baseline panic were more likely to report adequate 
doses of antidepressant treatment over 6 months of treatment and at the 6-month visit.  There 
are two possible explanations for the differential treatment patterns observed in this study.  
Because patients with baseline panic had more severe depressive symptoms at baseline and 
over the 6 months of treatment (results not shown) physicians may have treated these patients 
more aggressively.  Alternatively, physicians may have identified the comorbid panic 
symptoms, which in turn prompted more aggressive treatment.  If anything, this differential 
treatment might make our findings regarding the adverse impact of persistent panic 
symptoms on depression outcomes a conservative estimate.   
  Though we found no important effect of treatment adequacy in our regression 
analyses, this may a result of the limitations of our classification of adequate treatment.  Our 
definitions of adequacy of antidepressant treatment (treatment at month 6 at doses within the 
usual recommended dose range or treatment over the course of 6 months within the usual 
recommended dose range) are relatively simple classifications that incorporate doses at the 
low end of the effective range.  However, there is evidence that lower antidepressant doses 
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are commonly used in a primary care setting,134, 135 and antidepressant dosing in the ARTIST 
study was primarily in the lower end of the usual recommended dose range.125  This limited 
our ability to explore a more comprehensive definition of adequate treatment or to explore a 
relationship between dose and antidepressant response.  
 Finally, it is also important to consider how loss-to-follow-up would affect our 
results.  Over the initial 6 months of this longitudinal study, 16% of patients missed the 6-
month visit or were lost to follow-up.  We would expect that the more severe patients would 
be more likely to be lost to follow-up, which would likely lead to a weaker effect among 
those who remained in the study.  However, patients who were lost to follow-up were similar 
to patients who remained in the study in terms of baseline depressive severity, and results 
were similar when we imputed 6-month outcomes for those with missing data.   
 In conclusion, our study demonstrates that the presence of comorbid panic symptoms 
may negatively affect depression outcomes, particularly when panic symptoms persist 
despite antidepressant therapy, regardless of whether they meet the DSM criteria for panic 
attacks and panic disorder.  Therefore, it may be important to consider the presence of panic 
symptoms, both at baseline and over the course of depression treatment, when making 
treatment decisions in a primary care setting.  Future research should explore how 
improvements in panic symptoms affect depression outcomes, and should rely on clinical 
diagnoses or validated scales that provide information on the severity of the panic symptoms.  
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Table 13 (MS1 Table 1).  Usual minimum antidepressant dose 
 
Generic Name (Trade Name) Minimum Usual Daily Dose 
Amitriptyline (Elavil®) 150mg 
Bupropion (Wellbutrin®) 300mg 
Citalopram (Celexa®) 20mg 
Fluoxetine (Prozac®) 20mg 
Mirtazapine (Remeron ®) 15mg 
Nefazadone (Serzone®) 300mg 
Paroxetine (Paxil®)  20mg 
Sertraline (Zoloft®) 50mg 
Trazadone (Desyrel®) 300mg 
Venlafaxine (Effexor®) 125mg 
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Table 14 (MS1 Table 2). Baseline characteristics by baseline panic symptoms 
 
Characteristic Panic 
Symptoms 
No Panic 
Symptoms 
 (n=199) 
% 
 (n=370) 
% 
Gender   
 Female 81.9 77.6 
 Male 18.1 22.4 
Race   
 White 82.4 84.3 
 Other 17.6 15.7 
Depressive disorder diagnosis   
 Double Depression  52.7 44.5 
 Major Depression without dysthymia 37.2 34.8 
 Dysthymia only 4.8 9.0 
 Minor depression 5.3 11.6 
Past history of depression treatment   
 Yes 40.2 28.6 
 No 59.8 71.4 
Suicidal ideation in the past week   
 Yes 18.6 8.1 
 No 81.4 91.6 
 Don’t know 0 0.3 
Any alcohol use in the past month   
 Yes 42.7 46.2 
 No 57.3 53.8 
Any problems with alcohol in the past month   
 Yes 19.6 15.9 
 No 80.4 84.1 
Randomized Treatment   
 Fluoxetine hydrochloride 33.2 34.1 
 Paroxetine 32.7 33.2 
 Sertraline hydrochloride 34.2 32.7 
Treatment classification at month 6   
 Adequate 81.2 72.0 
 Inadequate 18.8 28.0 
Treatment classification over 6 months   
 Adequate 77.4 67.3 
 Inadequate 22.6 32.7 
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Table 15 (MS1 Table 3). Treatment response at month 6 by baseline panic symptoms* 
 
Depression Outcome at Month 6 Panic 
(n=161) 
No Panic 
(n=317) 
Unadjusted OR (95% 
CI) 
Remission 54 (33.5) 129 (40.7) 0.79 (0.51, 1.21) 
Partial Response 37 (23.0) 56 (56.3) 1.25 (0.75, 2.07) 
Nonresponse 70 (43.5) 132 (41.6) 1. 
* Overall Χ2 baseline panic symptoms by response was not significant (Χ2=6.53, degrees of 
freedom=2, p=0.3)  
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Table 16 (MS1 Table 4).  Association between baseline panic symptoms and depression 
outcome in primary care patients  
 
Analysis Adjusted OR (95% CI) * 
Complete Case (n=478)  
Remission  1.06 (0.67, 1.67) 
Partial Response 0.92 (0.54, 1.57) 
Nonresponse 1. 
Last Observation Carried Forward  (n=569)  
Remission  0.93 (0.61, 1.40) 
Partial Response 0.79 (0.48, 1.31) 
Nonresponse 1. 
Multiple Imputation (n=573)  
Remission  0.99 (0.64, 1.54) 
Partial Response 0.90 (0.54, 1.54) 
Nonresponse 1. 
Sensitivity Analysis (n=454)  
Remission  0.72 (0.16, 1.36) 
Partial Response 1.30 (0.59, 4.88) 
Nonresponse 1. 
*adjusted for baseline depression severity.  
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Table 17 (MS1 Table 5).  Treatment response at month 6 by persistent panic symptoms* 
Depression Outcome at Month 6 Yes 
(n=59) 
n (%) 
No  
(n=397) 
n (%) 
Unadjusted OR  
(95% CI) 
Remission 10 (17.0) 163 (41.1) 0.28 (0.14, 0.60) 
Partial Response 15 (25.4) 76 (19.1) 0.92 (0.47, 1.79) 
Nonresponse 34 (57.6) 158 (39.8) 1. 
* Overall Χ2 persistent panic symptoms by response was significant (Χ2=12.76, degrees of 
freedom = 2, p < 0.01)  
  
Table 18 (MS1 Table 6). Association between persistent panic symptoms and 
depression outcome in primary care patients  
Analysis Adjusted OR (95% CI) * 
Complete Case (n=456)  
Remission  0.38 (0.18, 0.81) 
Partial Response 0.66 (0.33, 1.33) 
Nonresponse 1.0 
Last Observation Carried Forward  (n=495)  
Remission  0.36 (0.18, 0.73) 
Partial Response 0.64 (0.33, 1.24) 
Nonresponse 1.0 
Multiple Imputation (n=573)  
Remission  0.32 (0.16, 0.67) 
Partial Response 0.63 (0.32, 1.23) 
Nonresponse 1.0 
Sensitivity Analysis (n=456)  
Remission  0.15 (0.02, 0.54) 
Partial Response 0.65 (0.16, 1.80) 
Nonresponse 1.0 
*adjusted for baseline depression severity.  
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Figure 1 (MS1 Figure 1).  Patient disposition enrollment through 6 months. 
 
Enrolled Patients  
(n=688) 
Randomized  
(n=601) 
Baseline Interview  
(n=573) 
Refused  
(n=87) 
No Panic Symptoms  
(n=370) 
Panic Symptoms  
(n=199) 
Completed 6 months of treatment 
(n=161) 
Completed 6 months of treatment 
(n=317) 
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Abstract 
Objective: To explore the effect of pain symptoms and improvements in pain on depression 
outcomes at month 6 in depressed primary care patients. 
Methods: We analyzed data from A Randomized Trial Investigating Selective Serotonin 
Reuptake Inhibitor (SSRI) Treatment (ARTIST), a randomized longitudinal effectiveness 
study comparing three SSRIs for the treatment of depression in a primary care setting 
(n=573).  Depression outcome at month 6, defined as remission, partial response, and 
nonresponse using the Symptom Checklist-20, was the primary outcome.   
Results: 80% of patients reported pain symptoms (defined using the PHQ-15 pain subscale) 
at baseline; 27% of patients with baseline pain reported improvement of at least 3-points on 
the PHQ-15 pain subscale from baseline to month 1.  Compared to patients with no pain at 
baseline, those with severe pain were less likely to achieve remission (OR=0.11, 95%CI 
0.05-0.25) and partial response (OR=0.24, 95%CI 0.10-0.59) vs. nonresponse.  Patients with 
moderate pain were less likely to achieve remission vs. nonresponse (OR=0.25, 95% CI 0.13-
0.48).  Patients with early improvement in pain were more likely to achieve remission 
(OR=1.90, 95% CI 1.03-3.49) and slightly more likely to achieve partial response (OR=1.24, 
95% CI 0.63-2.43).  The ORs increased slightly using a 2-point cut-off for early pain 
improvement.  Accounting for missing data with last observation carried forward or multiple 
imputation yielded similar results. 
Conclusion:  Pain symptoms are present in the majority of depressed primary care patients 
beginning antidepressant therapy.  Pain symptoms are associated with worse depression 
outcomes, while improvement in pain is associated with significantly better depression 
outcomes.  Attention to comorbid pain may be important in enhancing depression care.
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Introduction 
 More than half of depressed patients experience comorbid pain, including but not 
limited to headache, back pain, chest pain, gastrointestinal discomfort, and other body 
aches.10, 11, 85, 86  Most primary care patients with depression present with somatic rather than 
psychological complaints136, and pain accounts for more than half of all somatic 
complaints.137 While some suggest that physical symptoms should be considered as an 
important part of depression87, the DSM-IV criteria for a depressive episode comprise only a 
few somatic symptoms, among which pain is not included.16  In fact, depression may often 
go unrecognized when it presents with primarily somatic complaints.88  Not only do 
depression and pain frequently co-occur, they have reciprocal adverse effects on quality of 
life, disability, and health care use.10 
 Depression may be a risk factor for pain.87 Conversely, pain also may lead to 
development of depression.87  However, the efficacy of antidepressants in the treatment of 
pain is limited.  The tricyclic antidepressants have demonstrated efficacy in treating certain 
pain conditions.138, 139 Duloxetine, approved by the FDA in 2001, is effective for major 
depression, generalized anxiety disorder, and diabetic peripheral neuropathic pain.84  In 
contrast, the selective serotonin reuptake inhibitors (SSRIs) have uncertain efficacy in pain or 
in coexisting depression and pain.139, 140  However, a recent meta-analysis and systematic 
review of eight trials comparing duloxetine and paroxetine found insufficient evidence to 
support the choice of one antidepressant over the other for the treatment of pain 
accompanying depression.141     
 Although baseline pain appears to be associated with greater depression severity in 
specialty care settings and in the general population89-95, the effect of pain in depression 
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treatment outcomes in primary care settings have not been evaluated in depth.10, 101-105, 142, 143  
Primary care patients with depression and pain have worse depression outcomes.142, 143 and 
quality of life113 than those without comorbid pain.  Furthermore, pain improvement is 
associated with a reduction in depressive symptoms and patients without improvement in 
pain are less likely to experience remission.101-103   
 In A Randomized Trial Investigating SSRI Treatment (ARTIST), a primary care 
effectiveness study, pain severity was associated with baseline depression severity and 
baseline pain was a significant predictor of depression response at 3 months.104  Pain 
symptoms decreased during the first month of treatment and then remained fairly 
constant through month 9.105  Patients who experienced depression remission or partial 
response at months 1 and 3 had significantly greater improvement in their pain symptoms 
than nonresponders, and pain improvement was similar for patients experiencing 
remission and partial response.  However, these analyses did not explore confounding by 
panic symptoms or adequacy of antidepressant treatment.     
 In this report, our aim is to expand on the prior analyses of the ARTIST data by 
exploring: 1) the effect of baseline pain on depression treatment outcomes at month 6, 
and 2) the effect of early pain improvement on depression treatment outcomes at month 
6.  Examining outcomes at month 6 is important since this is a critical period for 
depression relapse, and adverse prognostic factors such as pain may be particularly 
salient in predicting relapse.  
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Methods 
 The ARTIST study methods, design, and population are described in detail elsewhere 
2
 and are summarized here.  
Design and Setting 
 ARTIST was a 9-month randomized, open-label, effectiveness trial comparing three 
SSRI antidepressants.2  Patients were enrolled from two primary care research networks: The 
Primary Care Network (n=51 study practitioners) and the primary care network from the 
Duke University Health System (n=26 study practitioners).   
Study Population 
 Patients 18 years of age and older were eligible for inclusion in the ARTIST trial if 
they visited a network primary care doctor between April and November 1999; the visits 
were not required to be depression related.  A depression diagnosis that was deemed 
appropriate for SSRI treatment and access to a telephone were also inclusion criteria.  
Patients were excluded if they were: actively suicidal; currently receiving treatment or had 
received treatment within the past 2 months with an SSRI; or currently taking a non-SSRI 
antidepressant either for depression (any dose level) or for a non-depressive disorder (at more 
than low doses, e.g. >50mg of amitriptyline or its equivalent); active substance abuse; 
pregnancy or breastfeeding; cognitive impairments (e.g., dementia or psychosis).  Additional 
exclusion criteria include an inability to read, speak, or write English, or a terminal illness.   
 Eligible patients were randomized to open-label treatment with one of three SSRIs 
(fluoxetine, paroxetine, sertraline) at the start of the study.  
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Study Measures 
Outcome 
 A Computer Assisted Telephone Interview (CATI) was used to assess outcomes 
at each study visit (baseline, and months 1, 3, 6, and 9).  Depression measures included 
the Primary Care Evaluation of Mental Disorders (PRIME-MD) depression module, 
which was used to assess the presence of depression,128 and the Symptom Checklist-20 
(SCL-20), which was used to assess depression severity.  The SCL-20 (range 0-4, with 
lower scores indicating better health) has been shown to detect differences in severity 
among treatment groups in primary care trials.115-117  In the current study, depression 
outcome was categorized as remission (SCL-20 score ≤ 0.5), partial response (≥ 50% 
improvement in SCL-20 score but not to a level of ≤ 0.5), and nonresponse (patients who 
do not meet either the remission or partial response criteria). 
Exposure 
 Pain was measured using the Patient Health Questionnaire-15 (PHQ-15) at baseline 
and months 1, 3, and 6 and the Short Form-36 (SF-36) at baseline and month 3.122  We 
focused primarily on the PHQ-15. 
 The PHQ-15 evaluates 15 different physical symptoms including 5 specific pain 
symptoms (headache, back pain, limb or joint pain, abdominal pain, and chest pain) with 
each pain item scored from 0 (“not bothered at all”) to 2 (“bothered a lot”).  Scores on the 
five specific pain items are summed to form a composite pain score (0 to 10) with higher 
scores indicating more pain.  For the current analysis, the PHQ-15 pain subscale was 
categorized into pain severity classes where scores of 0-2 indicates no pain, 3-4 indicates 
mild pain, 5-6 indicates moderate pain, and 7-10 indicates severe pain.104  The validity of the 
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PHQ-15 has been demonstrated in general internal medicine and family practice clinics as 
well as obstetrics-gynecology clinics.122  It has also proven responsive to change in treatment 
trials of patients with pain and other somatic symptoms.2, 144 
 The SF-36 bodily pain subscale includes two items, which address pain severity and 
pain interference; the overall score ranges from 0 to 100 (with 100 indicating best health 
status).  The SF-BP is a validated tool that is commonly used in psychiatric research.123  For 
the current analysis, we focused on the single pain severity question.  For the purposes of this 
analysis, pain was categorized as follows: “none” or “very mild” = none, “mild” = mild, 
“moderate” = moderate, and “severe” or “very severe” = severe pain.   
 Early pain improvement was defined as ≥ 3 point change from baseline to month 1 in 
the PHQ-15 pain score.  A 3-point change was used because it reflects the mean change from 
baseline to endpoint for patients treated with extended-release venlafaxine in anxious and/or 
depressed patients with multisomatoform disorder.124  Furthermore, a 3-point improvement in 
pain is approximately equal to a change in pain level when pain is categorized as none, mild, 
moderate, or severe using the PHQ-15 pain subscale.  To explore how sensitive the results 
were to our choice of pain change cut-off, we explored pain improvement defined as ≥ 2-
point change in pain score in the final regression model. 
Additional Demographic and Clinical Characteristics  
  The original ARTIST study captured demographic and additional clinical 
characteristics (e.g., prior treatment for depression, alcohol use, etc.), psychological 
measures, social function, work function, health-related quality of life, medication use, 
and healthcare utilization.  For the current analysis, the following covariates were of 
particular interest: age, race (white vs. other), sex, type of depression, initial SSRI 
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randomized, prior use of antidepressants, baseline problems with alcohol, baseline 
depression severity, symptoms of panic, and adequacy of antidepressant treatment.  
Adequacy of antidepressant treatment was explored in two ways.  Adequate treatment 
was defined using both dosing at the 6 month visit (treatment at month 6 above the 
minimum usual recommended dose, Table 1) and dosing over the course of the 6 months 
of study (treatment at each visit above the usual minimum recommended dose at each 
visit with no gaps in treatment greater than 2 weeks).   
  Because treatment of pain may affect our results, we also explored prior treatment 
with pain medications.  The pain medications reported at baseline included: non-steroidal 
anti-inflammatory drugs (ibuprofen, naproxen, Piroxicam®, Celebrex®, Vioxx®, 
Voltaren®, Lodine®, Relafen®, Daypro®), Tylenol®, aspirin, migraine/tension headache 
medications (Midrin®, Imitrex®), arthritis medications (Enbrel®), and other pain 
medications and muscle relaxants (including Ultram®, Vicodin®, Percocet®, Robaxin®, 
Valium®, Flexeril®, Skelaxin®, Soma®, Lortab®, Oxycontin®, MS Contin®, Fioricet®, 
Tylenol #3 with Codeine® and Tylox®). 
Statistical Analysis 
 The final multinomial logistic regression models were built using manual 
backward elimination change in estimate procedure, allowing us to explore the effects of 
each covariate in the presence of the other covariates.  The final models included the 
exposure of interest as well as any covariates that changed the odds ratio (OR) by greater 
than 10% for either comparison (remission vs. nonresponse; partial response vs. 
nonresponse).  EMM was assessed using the likelihood ratio test; any covariate with a 
significant likelihood ratio test (P < 0.20) where there was adequate sample size to 
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explore an interaction (>10 in each cell) was deemed an EMM.  Baseline depression 
severity was included as a covariate in all regression models evaluating the effect of 
baseline pain on depression outcomes.  Both baseline depression severity and baseline 
pain severity were included as covariates in the regression models evaluating the effect of 
pain improvement on depression outcomes.  Initial analyses included only those patients 
with complete data (complete case analysis).  
 Last observation carried forward and multiple imputation were used to assess the 
affect of missing data.  The last observed SCL-20 score was carried forward and used to 
create the outcome variable (depression outcome defined as remission, partial response, 
or nonresponse) in the last observation carried forward analysis.  The imputation 
algorithm included age, race, gender, problems with alcohol, alcohol use, baseline panic 
symptoms, baseline pain severity, SCL-20 score (months 1, 3, and 6), adequacy of 
depression treatment, and type of depression.  We used the imputed values to create the 
outcome variable, remission, partial response, or nonresponse at month 6.  SAS PROC 
LOGISTIC and SAS PROC MIANALYZE were used to generate the multinomial 
logistic regression parameter estimates and associated standard errors. 
 All analyses were run in SAS version 9.1.3 (SAS Institute, Cary, NC). 
 
Results 
 Of the 573 patients who completed the baseline assessments, 458 (80%) reported 
some level of pain: 190 (33%) reported mild pain, 165 (29%) reported moderate pain, and 
103 (18%) reported severe pain (Figure 1).  Most subjects (n=482, 84%) completed 6 months 
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of treatment:  of these treatment completers, 94 (19%) had no pain, 164 (34%) had mild pain, 
137 (28%) had moderate pain, and 87 (18%) had severe pain.   
 Several baseline and other clinical characteristics differed between patients with and 
without pain at baseline (Table 2).  Patients with baseline pain (mild, moderate, or severe 
pain) were younger [mild: 44.9 years (SD=15.7), moderate: 45.6 years (SD=15.6), and 
severe: 45.0 (SD=14.5) vs. no baseline pain: 49.0 (SD=17.1), respectively] and had greater 
depression severity at baseline as measured by the SCL-20 [mild: 1.55 (SD=0.68), moderate: 
1.77 (SD=0.68), and severe: 2.03 (SD=0.68) vs. no baseline pain: 1.34 (SD=0.78), 
respectively].  Patients with baseline pain were also more likely to have a diagnosis of double 
depression (depression with dysthymia) compared to patients with no pain at baseline.  
Compared to patients with no pain at baseline, those with moderate or severe pain were more 
likely to be female, have suicidal ideation in the past month, and have baseline panic 
symptoms, and were less likely to have a diagnosis of dysthymia only.  Patients with 
moderate pain were also more likely to have a prior history of depression treatment.   
Baseline Pain 
 Patients with moderate or severe baseline pain were much less likely to achieve 
remission at month 6 while patients with mild pain at baseline were only slightly less likely 
to achieve remission at month 6 compared to patients with no baseline pain (Table 3).  A 
similar pattern of results was seen in the partial response vs. nonresponse comparison though 
the effect is weaker. 
 In the multivariable analysis, adjusting for baseline depression severity and age, 
patients with severe pain as defined by the PHQ-15 pain subscale were much less likely to 
achieve remission (OR=0.11, 95% CI 0.05, 0.25) and partial response (OR=0.24, 95% CI 
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0.10, 0.59) vs. nonresponse at month 6 (Table 4).  Similarly, patients with moderate pain 
were much less likely to achieve remission (OR=0.25, 95% CI 0.13, 0.48) and were slightly 
less likely to achieve partial response (OR=0.65, 95% CI 0.30, 1.42) at month 6.  Mild 
baseline pain had a smaller effect on remission (OR=0.72, 95% CI 0.39, 1.32).  Overall, the 
results suggest an incremental effect of baseline pain on depression outcomes, as well as an 
incremental effect by depression outcome (remission vs. partial response).  Results were 
consistent using the LOCF and MI analyses (results not shown).      
 The results varied somewhat when we used the single SF-36 pain severity question to 
assess baseline pain symptoms (Table 4).  The remission vs. nonresponse comparison was 
similar in magnitude to that seen when the PHQ-15 pain subscale is used to classify pain 
severity, though the effect of severe pain was much weaker for partial response vs. 
nonresponse at month 6 (OR=0.75, 95% CI 0.32, 1.73).  The magnitude of the effect 
(remission vs. nonresponse) seen in patients with mild pain is much stronger when we define 
pain using the SF-36 pain severity question (OR=0.46, 95% CI 0.26, 0.81).  Results were 
consistent using the LOCF and MI analyses (results not shown).     
Pain Improvement 
 Of the 458 patients reporting any pain at baseline, 387 remained in the study and 
completed the 6-month visit and had information about both pain and depression, and 100 of 
the 387 patients (25.8%) experienced early pain improvement, defined as ≥ 3-point change in 
pain severity as measured by the PHQ-15 pain subscale from baseline to month 1.  There was 
no association of early pain improvement and depression outcome in the crude analysis 
(Table 5).  In the multivariate analysis, adjusting for age, baseline depression severity 
(baseline SCL-20 score), and baseline pain severity, early pain improvement was associated 
   90 
with better depression outcomes, particularly remission, at month 6 (remission vs. 
nonresponse OR=1.90, 95% CI 1.03, 3.49) (Table 6).  Results were similar in the LOCF and 
MI analyses.   
 The multinomial regression model was repeated with early pain improvement defined 
as ≥ 2-point improvement in pain as measured by the PHQ-15 pain subscale from baseline to 
month 1 (Table 6).  Overall, using the 2-point cut-off, there was a slightly stronger 
association between pain improvement and depression outcomes:  those with early pain 
improvement were much more likely to achieve remission vs. nonresponse (OR=2.97, 95% 
CI 1.73, 5.12).  Results were similar for the partial response vs. nonresponse comparison 
using both the 2- and 3-point cut-off.  Compared to the 3-point cut-off, the ORs are larger 
using the 2-point cut-off suggesting a strong association between early pain improvement and 
depression outcomes even when using a less conservative definition of early pain 
improvement. 
Discussion 
 Our results demonstrate that depression outcomes after 6 months of treatment are 
worse in patients with comorbid pain at baseline, which is consistent with prior studies 
conducted in a primary care setting.93, 104, 142, 143, 145  Furthermore, our results extend the 
analyses previously conducted in the ARTIST dataset,104 which evaluated the effect of 
baseline pain on depression and other health-related quality of life outcomes after 3 months 
of treatment using ARTIST, a primary care study of the effectiveness of SSRI treatment.  
Consistent with these results, we found an incremental effect with increasing pain severity.  
Additionally, we found the effect varied according to depression outcome, with a stronger 
effect seen in the remission vs. nonresponse comparison compared to the partial response vs. 
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nonresponse comparison.   With a few exceptions, the results were consistent whether we 
defined baseline pain using the PHQ-15 pain scale or the SF-36 pain severity question.  The 
differences between the results using the PHQ-15 pain subscale and the SF-36 likely arise 
because the categorization of pain is slightly different depending on the scale used to classify 
baseline pain severity.  There was a reduction in sample size, particularly for the comparison 
of partial response vs. nonresponse among patients with severe pain vs. no pain, which likely 
led to the change in the OR and the increase in imprecision of the estimates.    
 Though the presence of pain negatively affects depression outcomes, 93, 104, 142, 143, 145   
and can limit the effectiveness of depression interventions,142 improvement in pain is 
associated with improved depression outcomes.93, 105, 143  In the ARTIST study, remitters and 
partial responders had significantly greater changes in pain symptoms (measured using the 
PHQ-15 pain subscale) at both months 1 and 3.105  Most improvement in pain symptoms 
occurred during the first month of treatment.  Thus, we expanded these prior analyses by 
exploring how baseline pain and early improvement in pain affect depression outcomes at 6 
months.   
 We found that, among patients with any pain at baseline, early improvement of pain 
was associated with better depression outcomes at month 6, with an incremental effect 
according to depression outcome (remission and partial response).  The association between 
early pain improvement and improved depression outcomes, particularly depression 
remission, was observed using both a 2- and 3-point cut-off for early pain improvement.  In 
fact, a stronger relationship was observed between early pain improvement and remission 
using the less conservative 2-point cut-off, suggesting that even small improvements in pain 
result in significantly better depression outcomes.  As with the analyses of baseline pain, 
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there was evidence of an incremental effect, with a stronger effect observed for remission vs. 
nonresponse comparison and a weaker effect seen for partial response vs. nonresponse 
comparison.   
 While most improvement in pain symptoms occurred in the first month after the 
initiation of treatment, and our definition of pain improvement is based on this first month of 
treatment, it is unclear whether the pain improvement was a consequence of depression 
improvement or was due instead to a direct effect on antidepressants on pain symptoms.  
However, analyses in the ARTIST study have found a different time-course of results for 
pain and depressive symptoms, suggesting that physical symptoms are at least in part a 
separate entity from the depressive symptoms.105   We had insufficient sample size to explore 
how residual pain symptoms, or pain symptoms that persist despite antidepressant treatment, 
effect depression outcomes.   
 Differences between patients with and without baseline pain were observed in a 
number of demographic and clinical characteristics.  Our results are consistent with a cross-
sectional study of patients seen in the Kaiser Permanente network, which found that panic 
disorder was more common in patients with MDD and chronic disabling pain.113 We likewise 
found that panic symptoms were significantly more common in patients with moderate or 
severe baseline pain vs. no baseline pain.  However, the presence of panic was similar among 
patients with pain improvement compared to patients without pain improvement. 
  It is important to note the limitations of our definitions of adequacy of antidepressant 
treatment.  Our definitions of adequacy of antidepressant treatment are relatively simple 
classifications that incorporated doses at the low end of the effective range.  However, lower 
doses are commonly used in a primary care setting134, 135 and the  dosing in the ARTIST 
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study was primarily at the lower end of the recommended dose range (results not shown).  
Unfortunately, this limited our ability to explore a more comprehensive definition of 
adequate treatment or to explore a relationship between dose and antidepressant response.   
 Furthermore, any concomitant pain medication used during the study could have 
reduced pain scores, which in turn may have improved depression outcomes.  While we had 
information about baseline medications, including prescription and over the counter pain 
medications, we did not have information about the use of pain medications over the course 
of the study.  Therefore, we were unable to adjust for pain medication use over the course of 
the study, and future studies should seek to incorporate both baseline pain medications and 
medication use over the course of treatment.   
 An additional limitation is the heterogeneity of the depressed population in ARTIST 
population.  ARTIST included patients who had a depression diagnosis that was deemed 
appropriate for SSRI treatment.  Therefore, subjects in ARTIST had a variety of depression 
diagnoses, including double depression (major depression with dysthymia), dysthymia, and 
minor depression.  We would expect that the inclusion of less severe depressive diagnoses 
would dilute the effect, leading to a weaker relationship between pain and depression 
outcome.  However, results were similar in the subgroup of patients with MDD (results not 
shown).   
 In this 9-month longitudinal study, 16% of patients missed the 6-month visit or were 
lost to follow-up by month 6.  However, these patients were similar to patients who remained 
in the study in terms of baseline depressive severity, and results were similar when we 
imputed 6-month outcomes for those with missing data.   
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 Despite these limitations, our study demonstrates that comorbid pain symptoms 
negatively affect depression outcomes and early improvements in pain result in better 
depression outcomes.  Given that only about 30% of depressed patients experience remission, 
1
 the average visit to a PCP lasts only about 15 minutes8, 9, 19, 146 and diagnosis and treatment 
for depression must compete with other demands,20-23  it is critical that PCPs understand what 
factors are contributing to poor depression outcomes.  Our results suggest that identification 
of comorbid pain at the onset of depression treatment, as well as follow-up of those pain 
symptoms to resolution, may enhance depression outcomes in primary care.  Further research 
is warranted which prospectively explores the comparative effectiveness of currently 
approved antidepressants for the treatment of depression and comorbid pain.  In addition, the 
added value of pain-specific management strategies (e.g., optimized analgesic therapy, 
behavioral interventions) in patients with comorbid pain should be examined. 
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Table 19 (MS2 Table 1).  Minimum usual antidepressant dose 
Generic Name (Trade Name) Minimum Usual Daily Dose 
Amitriptyline (Elavil®) 150mg 
Bupropion (Wellbutrin®) 300mg 
Citalopram (Celexa®) 20mg 
Fluoxetine (Prozac®) 20mg 
Mirtazapine (Remeron ®) 15mg 
Nefazadone (Serzone®) 300mg 
Paroxetine (Paxil®)  20mg 
Sertraline (Zoloft®) 50mg 
Trazadone (Desyrel®) 300mg 
Venlafaxine (Effexor®) 125mg 
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Table 20 (MS2 Table 2).  Baseline demographic and clinical characteristics of patients 
by baseline pain severity (PHQ-15 pain subscale) 
 
 
Characteristic 
No Pain 
(n=115) 
% 
Mild  
(n=190) 
% 
Moderate 
(n=165) 
% 
Severe 
(n=103) 
% 
Female 68.7 77.9 82.4 87.4 
Race     
 White 86.1 82.6 85.4 80.6 
 Other 13.9 17.4 14.6 19.4 
Panic 20.9 28.4 40.0 53.4 
Depressive disorder diagnosis     
 Double Depression 25.2 37.4 50.3 53.4 
 Major Depression (no 
dysthymia) 
27.8 33.2 29.7 35.0 
 Dysthymia only 11.3 7.4 4.8 1.9 
 Minor depression 12.2 8.4 8.5 2.9 
 Other 23.5 13.7 6.7 6.8 
Past history of depression 
treatment 
25.2 29.5 41.2 32.0 
Any alcohol use in the past 
month 
45.2 49.0 57.0 59.2 
Any problems with alcohol in 
the past month 
16.5 19.5 12.7 20.4 
Any suicidal ideation in past 
month 
7.0 7.9 15.8 18.5 
Baseline treatment with pain 
medication 
14.8 10.0 19.4 20.4 
Randomized Treatment     
 Fluoxetine hydrochloride 40.0 31.1 32.7 33.0 
 Paroxetine 29.6 32.1 37.6 31.1 
 Sertraline hydrochloride 30.4 36.8 29.7 35.9 
Treatment classification at 
month 6 
    
 Adequate  59.1 62.1 68.5 66.0 
 Inadequate 22.6 25.3 15.8 22.3 
 Missing 18.3 12.6 15.8 11.7 
Treatment classification over 6 
months 
    
 Adequate  55.6 58.9 63.6 60.2 
 Inadequate 26.1 27.4 20.0 27.2 
 Missing 18.3 13.7 16.4 12.6 
 
  
Table 21 (MS2 Table 3).  Depression response at month 6 by baseline pain symptoms* 
 Baseline Pain Severity,  n (%)  Unadjusted OR (95% CI) 
Depression 
Outcome 
No Pain 
(n=94) 
Mild 
(n=164) 
Moderate 
(n=137) 
Severe 
(n=87) 
 Mild vs. 
No Pain 
Moderate vs. 
No Pain 
Severe vs. 
No Pain 
Remission 53 (56) 85 (52) 34 (25) 13 (15)  0.77 (0.43, 1.39) 0.24 (0.13, 0.45) 0.10 (0.05, 0.22) 
Partial Response 16 (17) 27 (16) 36 (26) 15 (17)  0.81 (0.37, 1.77) 0.84 (0.40, 1.77) 0.40 (0.17, 0.93) 
Nonresponse 25 (27) 52 (32) 67 (49) 59 (68)  1.0 1.0 1.0 
* Overall Χ2 baseline pain by depression response was significant (Χ2=63.95, degrees of freedom=9, p<0.0001) 
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Table 22 (MS2 Table 4).  Adjusted* OR (95% CI) for the association between baseline 
pain symptoms (measured using the PHQ-15 pain subscale and the SF-36 pain severity 
question) and depression outcome in primary care patients (complete case analysis) 
 
 Adjusted* OR (95% CI) 
 PHQ-15 pain subscale SF-36 pain severity 
Severe Pain    
Remission  0.11 (0.05, 0.25) 0.11 (0.05, 0.27) 
Partial Response 0.24 (0.10, 0.59) 0.75 (0.32, 1.73) 
Nonresponse 1.0 1.0 
Moderate Pain   
Remission  0.25 (0.13, 0.48) 0.33 (0.19, 0.58) 
Partial Response 0.65 (0.30, 1.42) 0.70 (0.33, 1.45) 
Nonresponse 1.0 1.0 
Mild Pain   
Remission  0.72 (0.39, 1.32) 0.46 (0.26, 0.81) 
Partial Response 0.67 (0.30, 1.52) 1.08 (0.51, 2.30) 
Nonresponse 1.0 1.0 
*PHQ adjusted for baseline depression severity and age; SF-36 adjusted for baseline 
depression severity, adequacy of antidepressant over 6 months, and baseline pain medication. 
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Table 23 (MS2 Table 5).  Depression response at month 6 by early pain improvement * 
 
 
Depression 
Outcome 
Early Pain 
Improvement 
(n=100) 
n (%) 
No Early Pain 
Improvement 
(n=287) 
n (%) 
Unadjusted OR 
(95% CI) 
Remission 35 (35) 97 (33.8) 1.09 (0.65, 1.83) 
Partial Response 21 (21) 57 (19.9) 1.11 (0.61, 2.04) 
Nonresponse 44 (44) 133 (46.3) 1.0 
* Overall Χ2 for pain improvement  by response was not significant (Χ2=0.17, degrees of 
freedom=2, p=0.92) 
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Table 24 (MS2 Table 6). Adjusted* OR (95% CIs) for the association between early 
pain improvement and depression outcome at month 6 in primary care patients 
(complete case analysis) 
 
 Adjusted* OR (95% CI) 
 3-point improvement 2-point improvement 
 
  
Remission  1.90 (1.03, 3.49) 2.97 (1.73, 5.12) 
Partial Response 1.24 (0.63, 2.43) 1.34 (0.74, 2.44) 
Nonresponse 1.0 1.0 
*adjusted for baseline depression severity, baseline pain severity, and age. 
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Figure 2 (MS2 Figure 1).  Patient disposition enrollment through 6 months. 
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CHAPTER VIII 
 
DISCUSSION 
VIII.  DISCUSSION 
Summary of Findings  
 This dissertation examined the association of two common comorbid conditions, 
panic and pain symptoms, with depression outcomes in a depressed primary care population.  
The research had three primary goals.  First, we explored the association of baseline and 
persistent panic symptoms on depression outcomes after 6 months of treatment (manuscript 
1).  Second, we explored the association of baseline pain symptoms on depression outcomes 
after 6 months of treatment (manuscript 2).  Third, we explored how early improvement in 
pain symptoms affected depression outcomes after 6 months of treatment (manuscript 2).   
 
Baseline Panic and Persistent Panic 
 In the first portion of this dissertation, we found that baseline panic symptoms were 
not associated with worse depression outcomes at month 6 (remission vs. nonresponse and 
partial response vs. nonresponse, subsequently referred to as “both regression models”).  
However, persistent panic was associated with worse depression outcomes.  Furthermore, 
there was evidence of an incremental response, with a stronger association with remission vs. 
nonresponse and a weaker association with partial response vs. nonresponse.  Adjustment for 
demographic and other clinical covariates had a minimal effect.  Results were similar using 
complete case analysis, last observation carried forward, and multiple imputation analysis.  
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Furthermore, the results of the sensitivity analysis demonstrate that our results are robust to 
varying the sensitivity and specificity across a wide range of values.  
 
Baseline Pain and Early Improvements in Pain 
 Our second manuscript aimed to explore how baseline pain symptoms and 
improvements in pain affect depression outcomes at 6 months in primary care patients.  We 
found that baseline pain was associated with worse depression outcomes at month 6, and 
there was evidence of an incremental effect with increasing pain severity.  Additionally, there 
was evidence of an incremental effect with a stronger association in the remission vs. 
nonresponse comparison than in the partial response vs. nonresponse comparison.  The 
results were consistent across different measures of pain (the PHQ-15 pain subscale and the 
SF-36 pain severity question).   
 Additionally, we explored the effect of early pain improvement (pain improvement 
from baseline to month 1) on depression treatment outcomes at month 6.  Among patients 
with any pain at baseline, early improvement of pain was associated with better depression 
outcomes at month 6.  Furthermore, early pain improvement was associated with higher odds 
of depression remission using both a 2- and 3-point cut-off to define early pain improvement.  
In fact, a stronger relationship was observed between early pain improvement and depression 
outcome using the less conservative 2-point cut-off, suggesting that even small 
improvements in pain result in significantly better depression outcomes.   
 In both pain analyses, adjustment for demographic and other clinical covariates had a 
minimal effect, with the exception of age.   
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Interpretation 
Baseline and Persistent Panic 
 Though the presence of baseline panic can negatively affect depression outcomes in 
both primary55, 63-65  and specialty38, 42, 43, 45, 47-54 care settings, we did not observe an 
association between baseline panic symptoms and depression outcomes.  However, our 
analysis, like prior analyses which have failed to demonstrate an association, 64, 65 relied on 
the use of a screening question to assess panic symptoms rather than a clinical diagnosis or a 
more comprehensive measure of panic severity.  To address this potential misclassification of 
our panic variable, we conducted a probabilistic sensitivity analysis.  The results were 
comparable to the complete case, last observation carried forward, and multiple imputation 
analyses, suggesting that our results are robust despite the use of a screening question.   
 Although we did not find an association between baseline panic symptoms and 
depression outcomes (remission or partial response) at month 6, we did find a strong 
association of persistent panic with depression outcome, particularly remission.  By requiring 
patients to have panic at baseline and at 3 months of follow-up, our definition of persistent 
panic may be associated with worse depression outcomes because it represents more severe 
or unremitting panic symptoms.  Alternatively, it may be a better indicator of the presence of 
panic disorder than baseline panic symptoms alone.  To our knowledge, this is the first 
analysis of the longitudinal effects of panic on depression treatment outcomes in a primary 
care setting.   
 Despite the use of a screening question for panic, our results are informative because 
we have identified that panic symptoms, regardless of whether they met DSM-IV criteria for 
panic attacks or disorder, can negatively affect depression outcomes when they persist 
despite antidepressant treatment.  This is particularly important because many of the 
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antidepressants, including the SSRIs, are also indicated for the treatment of panic disorder.  
Furthermore, the magnitude of the effect for persistent panic symptoms suggests that the 
presence of panic symptoms alone is enough to affect depression outcomes; it follows that 
the effect of panic disorder or panic attacks would result in an even greater effect.   
 
Baseline Pain and Early Improvements in Pain 
 Our results demonstrate that depression outcomes after 6 months of treatment are 
worse in patients with comorbid pain at baseline, which is consistent with prior studies 
conducted in a primary care setting.93, 104, 142, 143, 145  Furthermore, our results extend the 
analyses previously conducted in the ARTIST dataset,104 which evaluated the effect of 
baseline pain on depression and other health-related quality of life outcomes after 3 months 
of treatment using ARTIST, a primary care study of the effectiveness of SSRI treatment.  
Consistent with these results, we found an incremental effect with increasing pain severity.  
Additionally, we found an incremental effect according to depression outcome, with a 
stronger effect seen in the remission vs. nonresponse comparison compared to the partial 
response vs. nonresponse comparison.   
 Though the presence of pain negatively affects depression outcomes, 93, 104, 142, 143, 145   
and can limit the effectiveness of depression interventions,142 improvement in pain is 
associated with improved depression outcomes.93, 105, 143  Consistent with prior research,104 
we found that, among patients with any pain at baseline, early improvement of pain was 
associated with better depression outcomes at month 6, with an incremental effect according 
to depression outcome (remission and partial response).  Our analyses extend the previous 
findings by exploring depression outcomes in the maintenance phase of treatment and by 
exploring what the how baseline pain and early improvement in pain (pain improvement 
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from baseline to month 1) affect depression outcomes at 6 months.  Examining outcomes at 
month 6 is important since this is a critical time period for depression relapse, and adverse 
prognostic factors such as pain may be particularly salient in predicting relapse.  
 
Public Health Significance 
 Why is it important to understand the affect of panic and pain symptoms on 
depression outcomes in primary care patients?  Depression is common, affecting 
approximately 121 million people worldwide3 and most of the research on depression has 
been conducted in specialty care settings.  While the goal for depression treatment is 
remission, a large “real world” antidepressant effectiveness trial demonstrated that only about 
30% of patients experienced remission regardless of treatment setting (primary vs. specialty 
care).1   In order to effectively treat depressed patients, it is vital to understand what leads to 
70% of patients failing to meet remission, the goal of antidepressant treatment.   
 Depression is often treated in a primary care setting: approximately 10% of all visits 
are depression-related,5 nearly half the outpatient care for depression occurs in primary care 
settings,4 and the number of antidepressant visits is similar for primary and specialty care.6  
Furthermore, the average visit to a PCP lasts only about 15 minutes8, 9, 19, 146 and diagnosis 
and treatment for depression must compete with other demands.20-23  Given the time 
constraints and that most depression research has been conducted in specialty care settings, it 
is critical that PCPs understand the factors contributing to poor depression outcomes.   
 Finally, both comorbid anxiety and pain symptoms are common in depressed patients, 
occurring in approximately 65% (anxiety) to 80% (pain) of depressed patients.  Although 
other anxiety disorders may more commonly co-occur with depression, such as GAD and 
SAD, panic disorder is associated with severe disability and work impairment in patients 
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treated in primary care, even when the presence physical and depressive illness is controlled 
for.131 
 Finally, both panic and pain symptoms are treatable.  Because an improvement in 
these comorbid conditions leads to improved depression outcomes, it follows that a treatment 
strategy that focuses not only on depressive symptoms but also on these common comorbid 
conditions is warranted. 
 
Recommendations for Future Research  
 The results of this research suggest that the presence of both panic and pain 
symptoms are important to consider when treating depressed primary care patients.  To date, 
little is known about the effect of improvements in panic or pain on depression outcomes in 
primary care patients.  While our study sought to explore panic and pain improvements, there 
were some inherent limitations in the data.   
 Panic was measured using a screening question, rather than a clinical diagnosis.  
Though we were able to demonstrate that even symptoms of panic disorder negatively affect 
depression outcomes when they persist despite antidepressant treatment, we are unable to 
explore the effects of DSM-IV panic disorder or panic attacks.  Additionally, as we only had 
a dichotomous measure of panic, we were unable to fully explore how changes in panic 
affect depression outcomes.  However, our results suggest that panic that does not improve 
may be crucial to the improvement in depression.  Therefore, future research should explore 
not only baseline panic symptoms or panic disorder, but also the severity of panic symptoms, 
and changes in panic over the course of treatment.    
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 Our study demonstrated that the presence of baseline pain negatively affected 
depression outcomes and early pain improvement (both measured using the PHQ-15 pain 
subscale) led to significantly better depression outcomes.  The validity of the PHQ-15 has 
been demonstrated in general internal medicine and family practice clinics as well as 
obstetrics-gynecology clinics122 and it has also proven responsive to change in treatment 
trials of patients with pain and other somatic symptoms.2, 144  However, no research has 
explored the minimal clinically meaningful difference in pain score using this scale.  To 
define pain improvement, we used a 3-point change because it reflects the mean change from 
baseline to endpoint for patients treated with extended-release venlafaxine in anxious and/or 
depressed patients with multisomatoform disorder.124  Furthermore, a 3-point improvement in 
pain is approximately equal to a change in pain level when pain is categorized as none, mild, 
moderate, or severe using the PHQ-15 pain subscale.  Additionally, we re-analyzed the data 
using a 2-point cut-off to examine how sensitive our results were to our choice of cut-point.  
While our results demonstrated that even changes in pain of as little as 2 points significantly 
affect depression outcomes, definitions of clinically meaningfully differences on this 
validated scale should be explored and applied to future research. 
 Finally, while we did not find any evidence of confounding by adequacy of 
antidepressant treatment, our study was limited by relatively simple classifications of 
adequate antidepressant treatment that incorporated doses at the low end of the effective 
range.  Although the minimum dose was low, there is evidence that lower antidepressant 
doses are commonly used in a primary care setting,134, 135 and antidepressant dosing in the 
ARTIST study was primarily in the lower end of the usual recommended dose range.  This 
limited our ability to explore a more comprehensive definition of adequate treatment or to 
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explore a relationship between dose and antidepressant response.  However, future studies 
should incorporate comprehensive measures of treatment in order to assess the effect of 
treatment on depression outcomes, particularly among patients with other comorbid 
conditions, as adequacy of antidepressant dosing, particularly in populations where patients 
are treated with a greater range of doses, may affect treatment outcomes. 
 Finally, although we sought to examine comorbid panic and pain symptoms, we were 
unable to control for concurrent treatment of comorbid panic and pain symptoms.  The added 
value of pain-specific management strategies (e.g., optimized analgesic therapy, behavioral 
interventions) in patients with comorbid pain should be examined, as should anxiety-specific 
management strategies (e.g., optimized antidepressant or anxiolytic therapy, behavioral 
management) in patients with comorbid panic. 
  
APPENDICES 
APPENDIX A. ETHICAL REVIEW AND INFORMED CONSENT 
Ethical Review 
 This study was reviewed by the Institutional Review Board (IRB) of The 
University of North Carolina at Chapel Hill (Determination that Research or Research-
Like Activity does not require IRB Approval).  Because the study used de-identified data 
(with out access to key of identifiers) from the ARTIST study, the IRB determined that 
this activity does not constitute human subjects research as defined under federal 
regulations, and therefore did not require IRB approval.   
Informed Consent 
 Informed consent was not required for the current study; the original consent form 
for ARTIST covers secondary analysis of the data.  Data for the study were obtained 
already coded with an identification number and participant names were not be obtained.   
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APPENDIX B. RESULTS OF EARLY PAIN IMPROVEMENT ON DEPRESSION 
OUTCOMES AT MONTH 1 
 
 Because manuscript 2 provided a more informative analysis of early pain 
improvement on depression outcomes by focusing on results at Month 6 rather than at Month 
1, we did not include results from Month 1 analysis in either the dissertation or the 
manuscripts.  Results were similar at Month 1, though there is evidence of a stronger 
association and there is a substantial loss of precision. 
 Of the 458 patients reporting any pain at baseline, 436 remained in the study and 
completed the 1-month visit and 117 of these patients (27%) experienced early pain 
improvement, defined as ≥3-point change in pain severity as measured by the PHQ-15 pain 
subscale from baseline to month 1.  In the bivariate analysis, early pain improvement was 
associated with better depression outcomes at Month 1, mainly for remission but also for 
partial response (Table 25).  There was no association of early pain improvement and partial 
response in the crude analysis.   
 Similar to the bivariate analysis, the multivariate analysis indicated that early pain 
improvement was associated with better depression outcomes at Month 1, adjusting for age, 
baseline depression severity (baseline SCL-20 score), and baseline pain severity (Table 26).  
However, the association was stronger at month 1 than it was at month 6, and there was a 
loss of precision.  Results were similar in the last observation carried forward and multiple 
imputation analyses.   
 The multinomial regression model was repeated with early pain improvement defined 
as ≥ 2-point improvement in pain as measured by the PHQ-15 pain subscale from baseline to 
month 1 (Table 26).  Overall, using the 2-point cut-off, there was a slightly stronger 
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association between pain improvement and depression outcomes, with early pain 
improvement were much more likely to achieve remission vs. nonresponse and more likely to 
achieve partial response vs. nonresponse.  Compared to the 3-point cut-off, the ORs are 
larger using the 2-point cut-off suggesting a strong association between early pain 
improvement and depression outcomes even when a less conservative definition of early pain 
improvement is utilized. 
 Overall, the results at Month 1 are consistent with the results at Month 6 and support 
our overall conclusions.  Additionally, they support that early improvement in pain is 
associated with depression response as early as Month 1. 
Table 25 (Appendix B, Table 1).  Depression response at month 1 by early pain 
improvement * 
 
Depression 
Outcome 
Early Pain 
Improvement 
(n=117) 
n (%) 
No Early Pain 
Improvement 
(n=319) 
n (%) 
Unadjusted OR 
(95% CI) 
Remission 28 (24) 50 (16) 1.73 (1.01, 2.95) 
Partial Response 19 (16) 53 (17) 1.11 (0.61, 1.99) 
Nonresponse 70 (60) 216 (68) 1.0 
* Overall Χ2  for pain improvement by depression outcome was not significant (Χ2 = 0.17, 
degrees of freedom=2, p=0.92) 
 
 
Table 26 (Appendix B, Table 2).  Adjusted* OR And 95% CI for the association 
between early pain improvement and depression outcome at month 1 (complete case 
analysis) 
 
Adjusted * OR (95% CI) Depression  
Outcome 3-point improvement 2-point improvement 
Remission 3.20 (1.66, 6.16) 4.08 (2.21, 7.54) 
Partial Response 1.09 (0.57, 2.10) 1.81 (1.02, 3.23) 
Nonresponse 1.0 1.0 
* adjusted for baseline depression severity, baseline pain severity, and age. 
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